<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
	<title>Factiva</title>
<style type="text/css">body{margin:0;}form{margin:0;padding:0;}.icon a{display:block;}.nlFooter .icon a{display:inline-block!important;top:3px;}.icon span{display:none;}#postProcessingNav .icon{margin-right:15px;}#viewSelected,#viewSelected a{width:22px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:0 -212px;}#rtf,#rtf a{width:24px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-23px -212px;}#email,#email a{width:19px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-48px -212px;}#print,#print a{width:18px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-68px -212px;}#save,#save a{width:17px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-87px -212px;}#briefcase,#briefcase a{width:17px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-105px -212px;}#csv,#csv a{width:27px;height:17px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat top left;background-position:-125px -212px;}.modalNavGreen{background-color:#9C0;}.modalNavGreen td{vertical-align:middle;height:22px;padding:0 5px;white-space:nowrap;}td.modalTabGreen{height:18px;padding:0 10px 0 5px;vertical-align:bottom;background : url('../img/edgew.gif?42.27.0')  no-repeat right bottom;}td.modalTabWhite{background-color:#fff;height:18px;width:100%;padding:0;}span.tabTitle{color:#333;font-weight:bold;}a.supportLink{color:#55B0EB!important;float:right;vertical-align:top;text-decoration:none;}a.supportLink #helpIconCont{vertical-align:middle;width:19px;height:19px;}.modalSubTitle{position:relative;float:left;top:2px;margin-left:5px;}.modalTitle{position:relative;float:left;}.pipe{font-weight:normal;font-size:10px;color:#B5BACE;}span.checked{color:#A52A2A;font-weight:bold;}DIV.modalForm{background-color:#EEE;margin:10px 10px;}DIV.modalGgoup{width:auto;padding:10px;background-color:#D9DBE8;border-bottom:solid 1px #fff;border-top:solid 1px #fff;}DIV.modalGroupSpace{padding:3px;}.modalContainer{background-color:#EEE;padding:0 10px;}p.button-row{text-align:right;padding:0 10px;}.folderOpen .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -135px -110px transparent;width:21px;height:16px;margin-right:8px;float:left;}.folderClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -134px -94px transparent;width:18px;height:15px;margin-right:11px;float:left;}.groupOpen{padding:3px 0 3px 25px;background : url('../img/group_open.gif?42.27.0')  no-repeat left center;}.groupClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -85px -110px transparent;width:18px;height:15px;margin-right:11px;float:left;}.groupUnknown .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -182px -94px transparent;width:18px;height:14px;margin-right:11px;float:left;}.sharedOpen .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -153px -94px transparent;width:26px;height:15px;margin-right:3px;float:left;}.sharedClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -104px -110px transparent;width:26px;height:15px;margin-right:3px;float:left;}.folderTrigger .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat 0 -110px;width:16px;height:16px;margin-right:13px;float:left;}.folderClosed .itemText,.folderOpen .itemText,.groupClosed .itemText,.groupUnknown .itemText,.sharedOpen .itemText,.sharedClosed .itemText,.folderTrigger .itemText{margin-top:2px;float:left;}.folderClosed,.folderOpen,.groupClosed,.groupUnknown,.sharedOpen,.sharedClosed,.folderTrigger{margin:1px 0;}#folderDD .folderOpen,#folderList .folderOpen{padding-left:3px;}#folderDD .folderClosed,#folderList .folderClosed{padding-left:3px;height:inherit!important;}#folderDD .groupOpen,#folderList .groupOpen{padding-left:3px;}#folderDD .groupClosed,#folderList .groupClosed{padding-left:3px;}#folderDD .groupUnknown,#folderList .groupUnknown{padding-left:3px;}#folderDD .sharedOpen,#folderList .sharedOpen{padding-left:3px;}#folderDD .sharedClosed,#folderList .sharedClosed{padding-left:3px;}#folderDD .folderTrigger,#folderList .folderTrigger{padding-left:3px;}a.folderLink{color:#309;text-decoration:none;}a.folderLink:hover{color:#309;text-decoration:underline;}.onlineUBody{font-style:normal;font-weight:normal;}.padder{text-align:left;background-color:#DCDADA;}.spanheader{float:left;font-weight:bold;width:190px;}.spanheader2{float:left;text-align:right;font-weight:normal;width:auto;}.bol{font-weight:bold;}.padLks{width:100%;text-align:right;}table.usageHeader{background-color:#ffc;margin-top:.5em;padding:0 .5em;border:1px solid black;width:100%;}table.usageHeader th{text-align:left;}table.usageItems{background-color:#eee;border-bottom:2px solid #ccc;border-left:2px solid #ccc;border-right:2px solid #ccc;border-top:2px solid #ccc;width:100%;}table.usageItems thead tr td{background-color:#eee;font-weight:bold;padding-left:5px;color:#000;padding-bottom:0;padding-top:0;text-align:left;}table.usageItems tr,table.usageItems td{background-color:#fff;padding:15px;padding-bottom:0;padding-top:0;text-align:right;}table.usageItems td.first{text-align:left;width:33%;}table.usageItems th{text-align:right;font-weight:bold;}table.usageItems th.first{text-align:left;}table.usageItems tr.even td{background-color:#ffc;}table.usageItems th.whatIf,table.usageItems td.whatIf{color:#060;}table.usageItems tr.footer td{font-weight:bold;background-color:#eee;text-align:right;}table.usageItems tfoot td{font-weight:bold;background-color:#eee;text-align:right;color:#C06;}.APDATA{background-color:#ccc;margin-bottom:0;font-weight:bold;padding:4px;text-align:left;color:#000;}div.last{text-align:right;font-weight:bold;}.bold{font-weight:bold;vertical-align:top;white-space:nowrap;}.greenTable{border:1px solid #BD5;width:100%;}.applyBackGround{background-color:#BD5;}A.simpleLink{color:#000!important;background-color:transparent!important;font-weight:bold!important;}#narrowicon{width:16px;height:10px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -216px -62px;}#wideicon{width:16px;height:10px;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -232px -62px;}td.nrCol div a{display:inline-block;height:5px;margin:5px 0 0 5px;width:10px;overflow:hidden;}#uparrow{width:10px;height:5px;display:inline-block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -177px -67px;}#downarrow{width:10px;height:5px;display:inline-block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -177px -60px;}input.majorButton{background-color:#9C0;}input.minorButton{background-color:#CCC;}.errMsg{color:Red;}div.divFactivaException,div.divFactivaException table{background-color:#CCC;}div.divFactivaException table.subTable{background-color:#999;}div.loadingDiv{padding:10px 10px;text-align:center;font-weight:normal;}.colorLinks{color:Blue;}#listenArticle_link{margin:0 0 0 20px;}#cr_span{position:relative;float:left;clear:both;}#crIcon{position:relative;vertical-align:text-top;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -220px -21px;}.relInfoDiv{position:absolute;visibility:hidden;z-index:10000;border:solid 2px #999;border-top-color:#DEDEE9;border-left-color:#DEDEE9;background-color:#FBFBFE;width:450px;overflow:auto;height:auto;}.relInfo div.relInfoHeader{color:#666;padding:5px;border-bottom:solid 1px #DEDEE9;text-align:center;font-weight:bold;}.relInfo div.relInfoSubHeader{padding:5px;font-weight:bold;}.relInfo div.newLine{padding:0 5px 5px 5px;}.relInfo div.newLine a,.relInfo div.newLine a:visited{color:#54559B;text-decoration:none;}.relInfo div.newLine a:hover{text-decoration:underline;}#relInfoBody{padding:10px;}.popupCnt{background-color:#F2F3FB;position:absolute;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}.popupHdr{clear:both;background-color:#CCC;vertical-align:middle;padding:5px;height:15px;}div.floatRight{float:right;clear:right;}div.floatLeft{float:left;clear:left;}.popupHdr a.close{color:#309;text-decoration:none;}.popupHdr a.close:hover{color:#309;text-decoration:underline;}.dedupDiv{display:inline;white-space:nowrap;}.dedupDropdown{display:inline-block;white-space:nowrap;vertical-align:top;background:#dee3f1;color:#333;padding:0 0 3px 0;cursor:pointer;border:1px solid;border-top-color:#e9eefb;border-right-color:#99a3c3;border-bottom-color:#99a3c3;border-left-color:#e9eefb;}.dedupDropdown:hover{border-color:#B5BACE;text-decoration:none;}.dedupDropdown span{float:left;margin-left:4px;}.dedupDropdown .ddArrow{display:block;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -244px -195px;width:18px;height:14px;}.newIcon{vertical-align:middle;border:none;}.dedupMenu{display:none;position:absolute;z-index:10000;border:1px solid #999;background-color:#f5f6fb;width:360px;}.dedupMenu ul{list-style:none;margin:0;padding:0;text-align:left;}.dedupMenu li a{margin:0;padding:5px;cursor:pointer;display:block;text-decoration:none;outline:none;color:#000;white-space:normal;}.dedupMenu li a:hover{background-color:#C3C4FC;text-decoration:none;}.dedupMenu li.dedupSelected a{background-color:#DFDFFC!important;}#dedupState{font-weight:bold;vertical-align:top;}#dedupState2{font-weight:bold;}#hlpBox{background-color:#F2F3FB;position:absolute;width:400px;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}#ShowLatestBox{background-color:#F2F3FB;position:absolute;width:500px;height:auto;z-index:10000;visibility:hidden;border:1px solid #CCC;}#hlpBoxShim,#dedupMenuShim{position:absolute;visibility:hidden;left:0;top:0;}.srchHelp{padding:10px;}.srchHelp DIV{padding-bottom:5px;}.srchHelp OL,.srchHelp UL{margin-top:2px;}.srchHelp .OL{list-style-type:decimal;}.hplTable{padding:10px;overflow:hidden;}.hplTable table td{white-space:normal;}.BoxTL{padding-left:0;margin-right:1px;}.BoxTL .BoxTR{background-color:#E2E6F3;border:1px solid #8C92B1;padding-top:6px;}.BoxTL .BoxBR{padding-right:6px;}.BoxTL .BoxBL{padding:0 0 6px 6px;}input.majorBtn{background-color:#9C0;}.inputAlign{vertical-align:middle;}.xDialog{position:absolute;top:0;left:0;padding:1px;}.xDialog .header{clear:both;background-color:#CCC;vertical-align:middle;padding:5px;height:15px;color:#333;background:#FFF;font-weight:bold;background : url('../img/nlPopupTabBG.gif?42.27.0')  repeat-x right bottom;}.xDialog .header .close{position:absolute;display:block;top:3px;right:3px;overflow:hidden;}.xDialog .footer{position:relative;background-color:#FFF;padding:3px;}.xDialog .body{position:relative;position:relative;border-top:solid 1px #CCC;background-color:#FFF;height:auto;width:100%;}.xDialog .body .loading{background-color:#FFF;padding:3px;color:#333;font-weight:bold;}.PopupBackground{position:absolute;left:0;top:0;background:#A5A5A5;filter:alpha(opacity=60);opacity:.60;z-index:9999;}#appendAJAX{position:absolute;top:0;left:0;z-index:1000;}.mcemailPopupDialog{position:absolute;top:0;left:0;padding:1px;background : url('../img/mcemailpopupbg.png?42.27.0')  no-repeat left top;}.mobileCookieEmailDiv{position:relative;width:auto;display:block;padding:10px;height:150px;}.mobileCookieEmailDivPlaceholder{position:relative;width:auto;}#mobileCookieEmailDivPopup .buttons .btn{position:static!important;}#mobileCookieEmailDivHeader{font-weight:bold;}#mobileCookieEmailDivMsg3{position:relative;padding:10px;margin-left:70%;white-space:nowrap!important;}#mobileCookieEmailDivPopup{position:relative;margin-right:150px;}#mobileCookieEmailOnClickDiv{display:none;position:relative;vertical-align:top;margin-right:100px;}.odeMessage{color:#CE009C;font-weight:bold;}.edTableRowSeperator{background-color:#CCC;padding-top:1px;padding-bottom:1px;}.edLink{text-decoration:none;color:#648CAF;}.edLink:hover{text-decoration:none;color:#648CAF;}.edLinkPipe{font-family:Arial,Helvetica,sans-serif;color:#999;text-decoration:none;font-weight:normal;}.edTitleBold{font-weight:bold;}.edDescriptionSeperator{background-color:#999;padding-top:2px;padding-bottom:2px;}#translateArticleDiv{display:inline;}#translateArticleDiv a{color:#7C7EC9;text-decoration:none;}#translateArticleDiv img{padding-right:3px;margin-bottom:-2px;border:0;}#translateLanguagesDiv{display:none;position:absolute;border:solid 1px #999;z-index:1;}#translateLanguagesDiv.visiblek{display:inline;}#translateLanguagesDiv ul{list-style-type:none;list-style-position:outside;list-style-image:none;}.languagesDiv{background-color:#FBFBFE;border-color:#DEDEE9 #999999 #999 #DEDEE9;border-style:solid;border-width:2px;height:auto;overflow:auto;position:absolute;visibility:hidden;width:250px;z-index:10000;}#translateLanguagesDiv a,.languagesDiv #relInfoBody a{color:#000;background-color:#F0F0F0;padding-left:5px;padding-right:5px;display:block;}#translateLanguagesDiv a:hover,.languagesDiv #relInfoBody a:hover{background-color:#CCC;}.smb{height:44px!important;}#gl-navTopLeft-ADVISOR{position:absolute;top:0;left:0;background : url('../img/sprite_icons.gif?42.27.0')  no-repeat 0 -21px;width:215px;white-space:nowrap;}#djr1{position:absolute;right:5px;top:46px;width:183px;height:22px;background:#fff url(../img/djr-shadow.gif) no-repeat right top;z-index:9997;}#gl-navTopRightUl li#mbrightddtbm3 DIV{width:220px;}#gl-navTopRightUl li#mbrightddtbm3 ul,#gl-navTopRightUl li#mbrightddtbm3 ul li,#gl-navTopRightUl li#mbrightddtbm3 ul a{width:148px;width:200px;}#gl-navBottomMiddle ul li ul li div,#gl-navBottomMiddle ul li ul li div span{float:left;float:none;}#gl-navBottom div.gl-navBottomHolder{height:1px;font-size:.1em;}#gl-navBottomMiddle li.subMenuSpcr div{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -130px -94px;height:13px;width:1px;margin:0 2px;}#gl-navBottomMiddle li.subMenuSpcr div.EUPipe3{background:none;padding-right:6px;width:0;margin:0;}#gl-navBottomMiddle SPAN.fceSubMenuLabel{padding-left:5px;}#supportGreenLink{background : url('../img/dotcomgreen2.jpg?42.27.0')  no-repeat right top;padding:0 0 5px 0;height:19px;}#supportGreenLink a{color:#369;font-weight:bold;text-decoration:none;background : url('../img/dotcomgreen1.jpg?42.27.0')  no-repeat left top;padding:1px 6px 6px 6px;height:19px;}#supportGreenLink a:hover{color:#369;text-decoration:none;font-weight:bold;}td.supportGreenLink{vertical-align:top;height:22px;padding:0 5px;white-space:nowrap;padding-top:2px;}.feedBack{font-family:Arial,Helvetica,sans-serif;}.footerBG #djInsiderCtrl{display:inline;}#LinkFormExElem{display:none;}#NavAdPlaceHolder{position:absolute;top:6px;right:5px;height:18px;width:155px;font-weight:bold;text-align:center;vertical-align:middle;padding-top:1px;font-family:Arial,Helvetica,sans-serif;}#NavAdPlaceHolder a{color:#005596;}#uiVersion{color:#FFF;}#djimenu{margin:1px 0 0 0;padding:0;height:16px;}#djimenu img{border:none;vertical-align:top;margin-top:-2px;padding-right:8px;}#djimenu a{color:#000;font-weight:bold;text-decoration:none;height:16px;margin:0;padding:0 8px 0 0;font-family:Arial,Helvetica,sans-serif;}.mrm #gl-navBottom{background : url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x scroll 0 0 transparent!important;height:33px;padding:0 0 30px;position:relative;}.mrm #gl-navTopLeft h1{background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -105px transparent!important;width:300px!important;}.mrm #gl-navBottom{background : url('../img/sprite_bg_x_801px.jpg?42.27.0')  repeat-x top left;background-position:0 0;}.insight #gl-navTopLeft h1{background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -135px transparent!important;width:300px!important;background-color:#fff;}html>body #tblinkiff a{padding-top:4px;}.adContainer{position:relative;display:none;padding:0 0 10px 5px;}.adContainer_Login{position:static;display:none;padding:0 0 10px 5px;}.adContainer_Article{position:relative;display:none;padding:0 0 0 5px;}.article_Adwrapper{width:50%;float:right;height:125px;}.adHeader{float:right;}.adBody{clear:both;}a.helpLinkStyle,a.helpLinkStyle:visited{color:#55B0EB;text-decoration:none;cursor:pointer;}a.helpLinkUnderLine,a.helpLinkUnderLine:visited{text-decoration:underline!important;}a.tsLinkStyle,a.tsLinkStyle:visited{color:#800080!important;text-decoration:none;}a.tsLinkUnderLine,a.tsLinkUnderLine:visited{text-decoration:underline!important;}a.tsLinkStyle:hover{color:#800080!important;text-decoration:underline!important;}div.dbgViewXmlFormat{background-color:#000;color:#32cd32;}.brwsLbl{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -250px -73px;}.lkpBar .lkpBtn.wsjLkpBtn{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -241px -21px;}#fiiInstruction{background : url('../img/sprite_bg_x_1px.gif?42.27.0')  repeat-x top left;}#fiiInstruction TD.pnlsTtl div.separator{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -132px -94px;}.tblNav .tblToggleBtn{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -40px transparent;}.tblNav .tblToggleBtn.tblToggleBtnPlus{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -20px transparent;}.firstDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -323px transparent;*display:inline-block;*position:relative;*top:2px;}.secondDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll -2px -343px transparent;}.scheduledDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -382px transparent;}.continuousDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -363px transparent;}.onlineDel{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -683px transparent;}.emptyDel{background:none;}.xmlLink.xmlLinkWithIcon,.xmlLink.xmlLinkWithIcon a:hover{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -400px transparent!important;}.xmlLinkWithIcon{background : url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat -340px -3px transparent;}.xmlLinkWithIcon:hover{background : url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat -338px -26px transparent;}html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,font,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr{margin:0;padding:0;border:0;outline:0;font-size:100%;background:transparent;font-weight:normal;}.sbTable td{margin:0;padding:0;border:0;outline:0;font-size:100%;background:transparent;font-weight:normal;}body{line-height:1;background-color:#FFF!important;}ol,ul{list-style:none;}blockquote,q{quotes:none;}blockquote:before,blockquote:after,q:before,q:after{content:'';content:none;}select{font-size:1em;padding:1px;}:focus{outline:0;}ins{text-decoration:none;}del{text-decoration:line-through;}table{border-collapse:collapse;border-spacing:0;}body{text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:72.5%;line-height:normal;color:#666;}div,table,td{font-size:1em;}h1,h2,h3,h4,h5,h6{font-size:1em;}p img.left{float:left;margin:1.5em 1.5em 1.5em 0;padding:0;}p img.right{float:right;margin:1.5em 0 1.5em 1.5em;}a{color:#55b0eb;text-decoration:none;}a:focus,a:hover{color:#666;text-decoration:none;}body{margin:0;}#contentWrapper{padding:0 15px;}.WorkSpace .wsList{padding:0!important;}#gl-navContainer{z-index:800;position:relative;width:98%;margin-left:10px;}#gl-navTop{height:33px;background-image:none;background-color:#fff;z-index:810;}#gl-navTop table{height:33px;vertical-align:middle;background-color:#fff;}#gl-navTop table td{vertical-align:middle;}#gl-navTop #gl-navTopLeft{vertical-align:top;padding-left:15px;}#gl-navTop #gl-navTopLeft h1{width:123px;height:20px;font-size:.1em;text-indent:-9999px;background : url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat 0 -209px #fff;margin:0;padding:0;position:relative;top:6px;}#gl-navTop #gl-navTopRight{padding-right:15px;}#gl-navTopRightUl{float:right;z-index:9997;margin:0;}#gl-navTopRightUl li.userNavItem{float:left;height:12px;position:relative;line-height:12px;padding:0 7px;border-right:1px solid #ccc;z-index:9998;}#gl-navTopRightUl li#mbrightddtbm241{border:none;}#gl-navTopRightUl li a{display:block;line-height:10px;margin-bottom:1px;}#gl-navTopRightUl li a:hover,#gl-navTopRightUl li.over a{color:#55b0eb;}#gl-navTopRightUl li#mbrightddtbm1,#gl-navTopRightUl li#mbrightddtbm0{padding-right:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat right -4px;}#gl-navTopRightUl li#myDJFmenu{background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat left -64px;}#gl-navTopRightUl li.over{background-color:#333;}#gl-navTopRightUl li#mbrightddtbm241{padding-right:6px;}#gl-navTopMiddle a,#gl-navTopRightUl a{color:#666;margin:0;}#gl-navTopRightUl #myDJFmenu a{padding-left:12px;}#gl-navContainer a,#gl-navContainer a:hover{color:#4D5926;text-decoration:none;}#gl-navTopRightUl #mbrightddtbm0 div,#gl-navTopRightUl li .settingsToolsDrop{position:absolute;top:12px;right:0;background-color:#333;padding:5px;border:1px solid #000;z-index:9999;}#gl-navTopRightUl li .settingsToolsDrop{width:450px;_width:452px;}#gl-navTopRightUl li div{display:none;}#gl-navTopRightUl li.over div{display:block;}#gl-navTopRightUl li .settingsToolsDrop div{float:left;width:150px;}#gl-navTopRightUl li .settingsToolsDrop div .sectionTitle{color:#55b0eb;font:normal 1.1em Arial,Helvetica,sans-serif;line-height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 0;margin:0;padding-left:20px;}#gl-navTopRightUl li .settingsToolsDrop div .Tools{background-position:0 -160px;}#gl-navTopRightUl li .settingsToolsDrop div .Lists{background-position:0 -200px;}#gl-navTopRightUl li .settingsToolsDrop div .Language{background-position:0 -240px;}#gl-navTopRightUl li .settingsToolsDrop div .Account{background-position:0 -220px;}#gl-navTopRightUl li .settingsToolsDrop div .Settings{background-position:0 -180px;}#gl-navTopRightUl #mbrightddtbm0 div ul,#gl-navTopRightUl li .settingsToolsDrop div ul{background:none;padding:0;}#gl-navTopRightUl #mbrightddtbm0 div ul{width:250px;}#gl-navTopRightUl li .settingsToolsDrop div ul{margin-bottom:10px;}#gl-navTopRightUl #mbrightddtbm0 div ul li,#gl-navTopRightUl li .settingsToolsDrop div ul li{background:none;border:none;}#gl-navTopRightUl #mbrightddtbm0 div ul li a,#gl-navTopRightUl li .settingsToolsDrop div ul li a{display:block;color:#fff;background:none;padding:3px 20px 3px 10px;white-space:normal;}#gl-navTopRightUl #mbrightddtbm0 div ul li a:hover,#gl-navTopRightUl li .settingsToolsDrop div ul li a:hover{background:none;border:none;color:#333;background-color:#f4f4f4;}#gl-navBottomMiddle ul li.selected ul.selected li.subMenuSpcr{display:none;}#gl-navBottom{height:33px;position:relative;background: transparent url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x 0 0;padding:0 0 30px;}#gl-navBottomMiddle{height:33px;width:100%!important;background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat right -132px;}#gl-navBottomMiddle ul#menulist{height:33px;background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 -99px;padding:0;margin:0;}#gl-navBottomMiddle ul li{float:left;margin:0;padding:0 0 0 15px;cursor:pointer;}#gl-navBottomMiddle ul li.selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 0;}#gl-navBottomMiddle ul li.first-selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.png?42.27.0')  no-repeat 0 -33px;}#gl-navBottomMiddle ul li a{display:block;float:none;color:#afafaf;cursor:pointer;line-height:33px;background:none;outline:none;padding:0 10px 0 0;}#gl-navBottomMiddle ul li a:hover{color:#afafaf;}#gl-navBottomMiddle ul li.selected a{font-weight:normal;color:#fff;background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -66px;cursor:pointer;}#gl-navBottomMiddle ul li.selected a:hover{color:#fff;}#gl-navBottomMiddle ul li ul{display:none;}#gl-navBottomMiddle ul li.selected ul.selected{display:block;min-width:600px;height:30px;position:absolute;top:33px;left:0;padding:0 15px;cursor:default;}* html #gl-navBottomMiddle ul li.selected ul.selected{width:750px;}#gl-navBottomMiddle ul li.selected ul.selected li{float:left;display:inline-block;height:30px;margin-right:10px;padding:0;white-space:nowrap;}#gl-navBottomMiddle ul li.selected ul.selected li a{display:inline;height:30px;color:#666;line-height:30px;background:none;padding:0;cursor:pointer;}#gl-navBottomMiddle ul li.selected ul.selected li a:hover{color:#55b0eb;}#gl-navBottomMiddle ul li.selected ul.selected li a.selectedSubMenu{color:#55b0eb;font-weight:normal!important;}#mentionedLabel1{z-index:710;}#mentionedLabel1 div{z-index:725;}#pageFooter{background: transparent url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;padding:10px 15px 5px;height:10px;}#pageFooter .shadowL,#pageFooter .shadowR{display:none!important;}.footerBrand{width:101px;background: transparent url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -40px;margin:0;}.ftright{width:66px;background: transparent url('../img/facelift/facelift-brand-sprite.png?42.27.0')  no-repeat scroll 0 -80px;}#pageFooter .copyright{color:#666;line-height:normal;}.footerBG .feedBack,.feedBack:hover,.footerBG .whatsNew,.whatsNew:hover,.footerBG .privacy,.privacy:hover,.footerBG .djinsider,.djinsider:hover,.footerBG #djInsiderCtrl a,.footerBG #djInsiderCtrl a:hover{color:#666!important;line-height:normal!important;border-right:1px solid #666!important;padding:0 5px!important;}.footerBG .privacy,.privacy:hover{margin-right:10px;border:none;}.footerBG .pipe{display:none;}.simpleSearchBottom:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.simpleSearchBottom,.clearFix{zoom:1;}* html .simpleSearchBottom,* html .clearFix{height:1%;}.clear{clear:both;height:0;overflow:hidden;}.ac_input{font:Arial,Helvetica,sans-serif!important;}.ssTable{width:100%;}.ssTable td{vertical-align:top;}.ssTable .shadowLeft{width:10px;height:20px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  no-repeat 0 0;}.ssTable .ssTextBox{height:26px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  repeat-x 0 -56px;}.ssTable .shadowRight{width:12px;height:20px;background: transparent url('../img/facelift/facelift-SStextbox-sprite.gif?42.27.0')  no-repeat 0 -28px;}.ssTable .ssTextBox input{width:100%;mn-height:17px;line-height:13px;background:none;border:none;margin:0;padding-top:6px;outline:none;}.simpleSearchBottom{padding:5px 0;}.simpleSearchSelectSource{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;margin-right:10px;}.simpleSearchSelectDate{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.ssSubmit{float:right;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.ssSubmit ul.buttons{float:left;display:-moz-inline-stack;display:inline-block;height:26px;vertical-align:middle;}.columnsCntr ul{list-style:none;}.columnsCntr #LtCol,.columnsCntr #MdCol,.columnsCntr #RtCol{float:left;width:300px;margin-right:30px;}.columnsCntr #RtCol{width:300px;}wHeaderBar{margin-bottom:10px;}.wHeaderTtl span{display:block;color:#007ec5;font:bold 1.6em Arial,Helvetica,sans-serif;padding:0 5px;}.wBodyMax ul li{padding-bottom:3px;}.wBodyMax ul li a{display:block;color:#333;padding:0 5px;}.wBodyMax ul li a:hover{background-color:#f0f0f0;}#dateAndDupRow:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}#dateAndDupRow,.clearFix{zoom:1;}* html #dateAndDupRow,* html .clearFix{height:1%;}.clear{clear:both;height:0;overflow:hidden;}.sbTable{width:100%;}.sbTable .shadowTopLeft{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px 0;}.sbTable .shadowTopMid{height:12px;background: transparent url('../img/facelift/facelift-repeatingBG-sprite2.png?42.27.0')  repeat-x 0 -33px;}.sbTable .shadowTopRight{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -12px;}.sbTable .shadowLeft{width:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  repeat-y 0 0;}.sbTable .sbTextBox{background-color:#fff;}.sbTable .shadowRight{width:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  repeat-y -12px 0;}.sbTable .shadowBotLeft{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -36px;}.sbTable .shadowBotMid{height:12px;background: transparent url('../img/facelift/facelift-repeatingBG-sprite.png?42.27.0')  repeat-x 0 -45px;}.sbTable .shadowBotRight{width:12px;height:12px;background: transparent url('../img/facelift/facelift-textbox-sprite.png?42.27.0')  no-repeat -24px -24px;}.sbTable .sbTextBox .searchBuilder{width:100%;background:none;border:none;margin:0;outline:none;font:Arial,Helvetica,sans-serif!important;}.blur{color:#ccc;}.txtWrapperDiv{background:#fff url(../img/facelift/shadowRepeating.png) repeat-x 0 bottom;}.txtWrapperDiv div.shadowL,.txtWrapperDiv div.shadowR{height:20px;}.txtWrapperDiv div.shadowL{background : url('../img/facelift/shadowLeft.png?42.27.0')  no-repeat 0 0;}.txtWrapperDiv div.shadowR{background : url('../img/facelift/shadowRight.png?42.27.0')  no-repeat right 0;}.searchFormDiv td input{width:80%;}.searchToggleSwitchWrap{padding:0 15px;}.freeTextSwitch{border-bottom:1px solid #fff;border-top:1px solid #fff;}.searchFormSwitch{border-bottom:1px solid #fff;}.freeTextSwitch a,.searchFormSwitch a{display:block;color:#666;text-decoration:none;padding:5px 10px;}.freeTextSwitch a:hover,.searchFormSwitch a:hover{text-decoration:none;}.selected a{color:#55b0eb;cursor:default;}.selected a:hover{cursor:default;}.searchToggleBoxWrap{background-color:#F0F0F0;border:1px solid #E7E7E7;padding:10px 0 10px 0;}.searchToggleBoxWrap .col1{width:170px;}.searchToggleBoxWrap .col2{margin-left:170px;float:none!important;}#textAndConceptContainer{position:relative;padding:0 10px 0 0;}.sbTableWrap a{display:block;position:absolute;left:-249px;top:60px;color:#666;font:normal .9em Arial,Helvetica,sans-serif;text-decoration:none;}.sbTableWrap a:hover{color:#55b0eb;}.exampleLink{display:none;padding:10px 0 0 11px;}.exampleLink a{color:#666;font:normal .9em Arial,Helvetica,sans-serif;text-decoration:none;}.fcsclose,.fcsopen{display:block;height:20px;font-weight:bold;line-height:20px;background-image : url('../img/facelift/facelift-icon-sprite.png?42.27.0') ;background-repeat:no-repeat;cursor:pointer;padding:0 0 0 20px;}.fcsclose{background-position:0 -119px;}.fcsopen{background-position:0 -140px;}#dateAndDupRow{padding:10px 0 0 0;}#dateAndDupRow .sbFld{float:left;margin-right:20px;padding:0;}#dateAndDupRow #datePnl{float:left;top:-5px;}.sbFld label{margin:0 5px;}.pnlTab{cursor:pointer;padding:0 5px 0 20px;width:175px;vertical-align:top;height:22px;}.pnlTabOpen{cursor:pointer;width:175px;padding:0 5px 0 20px;vertical-align:top;}.pnlTab .pnlTabArrow{float:right;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -20px;}.pnlTabOpen .pnlTabArrow{float:right;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -40px;}.pnlTrTab .pnlLst{border-bottom:1px solid #f0f0f0;}.pnlLbl{padding:15px 10px 0 10px;}.pnlTrTabOpen .pnlLst{border:none;}.lkpBar{padding:10px 0;}.lkpBar .lkpBtn{float:left;width:20px;height:20px;background: transparent url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -80px;margin-left:5px;cursor:pointer;}.pnlFrm{padding-bottom:10px;}.pnlMnu{border:1px solid #e7e7e7;}.pnlMnu .mnuHdr,.rsltHdr{color:#666;font:bold 1.2em Arial,Helvetica,sans-serif;padding:0 0 10px;}a.sbIcon{display:-moz-inline-stack;display:inline-block;width:20px;height:10px;position:static;background:none!important;}a.sbIcon img{display:inline!important;}.sbForm .edit{color:#55B0EB;}#moreSearchRootCont #moreOptsWrp{float:left;margin-right:50px;width:50%;}#moreOptsWrp .headlineViewAs{float:left;margin:5px 5px 5px 0;}#moreOptsWrp .headlineViewAs .viewAsMenu{left:0!important;right:auto;}#moreSearchRootCont #adcntrlPnl{float:left;margin-left:10px;}.botButtonWrap{margin:10px 0;}.botButtonWrap .buttons{float:right;}.columnsCntr:after,.botButtonWrap:after,.snapshotthemes:after,#fdtHldContainer:after,#searchBuilderBoxWrap:after,.cd_div_collapse:after,.ctTab:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.columnsCntr,.botButtonWrap,.snapshotthemes,#fdtHldContainer,#searchBuilderBoxWrap,.cd_div_collapse,.ctTab,.clearFix{zoom:1;}* html .columnsCntr,* html .botButtonWrap,* html .snapshotthemes,* html #fdtHldContainer,* html #searchBuilderBoxWrap,* html .cd_div_collapse,* html .ctTab,* html .clearFix{height:1%;}#searchBuilderBoxWrap{padding-top:6px;clear:both;}#headlineTabs{margin:8px 0 0;padding:5px 0 0;background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;z-index:10;top:1px;}#editws span.shadowL,#editws span.shadowR{display:none!important;}span.shadowL{left:-29px;background : url('../img/facelift/shadowLeft.png?42.27.0')  no-repeat 0 0;}span.shadowR{right:-29px;background : url('../img/facelift/shadowRight.png?42.27.0')  no-repeat 0 0;}* html span.shadowR{right:-15px;}#pageFooter .shadowL{left:-15px;}#pageFooter .shadowR{right:-15px;}.ctTab{list-style:none;padding:0 10px 5px;}.ctTab .tabOff,.ctTab .tabOn{margin-right:10px;}.ctTab .tabOff a{color:#666;font-size:1.1em;text-decoration:none;}.ctTab .tabOff a:hover{color:#333;}.ctTab .tabOff a span{margin-left:2px;}.ctTab .tabOn span{color:#55B0EB;font-size:1.1em;}.fdtContainer{float:left;width:241px;}#fdtWrapper{overflow:auto;position:relative;}.cd_header{cursor:move;position:relative;}.cd_export{padding:3px;position:relative;top:0;z-index:3;color:#666;float:right;}.cd_expand{height:20px;width:20px;position:absolute;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -420px transparent;margin:1px 0 0 20px;z-index:998;}* html .cd_expand{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -420px transparent;}.cd_collapse{height:20px;width:20px;position:absolute;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -460px transparent;margin:1px 0 0 20px;z-index:998;}* html .cd_collapse{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -460px transparent;}.cd_headerA{color:#999;text-decoration:none;}.cd .cd_header .cd_export a:hover{text-decoration:underline;}.cd_title{position:relative;font-weight:bold;margin:0;padding:5px 3px 5px 45px;cursor:move;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -659px transparent;}#snapsnapshotthemesContent{padding:0 0 5px 20px;}ul.snapshotthemes{margin:0;padding:0;list-style:none;}ul.snapshotthemes li{float:left;display:inline;margin-right:6px;white-space:nowrap;}ul.snapshotthemes li a{float:left;line-height:20px;text-transform:lowercase;}.newsThemes1 a{font-size:.9em;}.newsThemes3 a{font-size:.9em;}.newsThemes5 a{font-size:1em;}.newsThemes7 a{font-size:1.1em;}.newsThemes9 a{font-size:1.2em;}.newsThemes11 a{font-size:1.3em;}.newsThemes13 a{font-size:1.4em;}.newsThemes15 a{font-size:1.4em;}.newsThemes17 a{font-size:1.5em;}.newsThemes19 a{font-size:1.6em;}#fdtBar{float:left;width:10px;height:100%;cursor:pointer;}.fdtHldContainer #fdtBar{background:#efefef url(../img/facelift/handles-sprite.png) no-repeat 0 center;}.fdtHldContainerOff #fdtBar{background:#EFEFEF url(../img/facelift/handles-sprite.png) no-repeat -10px center;}.quoteRow:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.quoteRow,.clearFix{zoom:1;}* html .quoteRow,* html .clearFix{height:1%;}div.recognition,#appliedFilters{padding:5px 10px;}div.recognition{font-weight:bold;background-color:#ffffe3;}#appliedFilters .filter{font-weight:bold;float:left;}.nofloat{float:none!important;}.DJIIFilterList .beta{float:left;padding-top:2px;padding-right:5px;}#appliedFilters .DJIIFilterList .beta{float:left;padding-top:0!important;padding-right:5px;}#articleFrame #appliedFilters{padding-top:0!important;}#articleFrame #appliedFilters .DJIIFilterList .beta{float:none!important;padding-top:0!important;padding-right:5px;}#newsFilterLst .DJIIFilterList .beta{padding-top:1px!important;}.recognition .suggested a{color:#007ec5;font-weight:bold;}div.quoteRow .quote{display:block;float:left;}div.quoteRow .quoteLinks{display:block;float:left;padding-left:5px;}.quoteLinks a{color:#007ec5;padding:0 5px;border-left:1px solid #666;}.quoteLinks a:hover{text-decoration:underline;}.change-up-new{text-align:right;padding-right:12px;}.change-down-new{text-align:right;padding-right:12px;}#hldContainer{margin:0 0 0 251px;border-left:solid 1px #CCC;}#resultHeader{margin:0 0 0 251px;border-left:solid 1px #CCC;}.splitterContainer{position:relative;overflow:visible;visibility:visible;height:100%;padding:0;background:transparent;border:none;}.clsSplitter{position:absolute;overflow:hidden;visibility:hidden;margin:0;padding:0;border:none;}.clsPane{position:absolute;visibility:visible;margin:0;padding:0;border:none;}.clsPane{overflow:visible;}.clsPane{overflow:auto;}.headlinesView{margin:0!important;overflow-x:hidden;}.headlinesView body.articleView .clsDragBar,body.headlinesView .clsDragBar{visibility:hidden;}.clsDragBar{position:absolute;overflow:hidden;visibility:visible;margin:0;padding:0;background:#CCC;border:none;}#headlineFrame,body.articleView #articleFrame{border-left:solid 3px #EEE;border-right:solid 3px #EEE;border-bottom:solid 3px #EEE;}#articleFrame,#headlineFrame{border:none;}#headlineFrame,body.articleView #articleFrame{border:none;}#hldSplitterBar{background:#EFEFEF url(../img/facelift/handles-sprite.png) no-repeat -20px center;}#headlineFrame{height:100%;overflow:hidden;}body.headlinesView #headlineFrame,body.articleView #articleFrame{float:none;width:auto;display:block;}body.headlinesView #headlineFrame{border-left:solid 1px #FFF;}.headlineHeader{padding:5px 5px 8px 0;background : url('../img/facelift/shadowRepeating2.png?42.27.0')  repeat-x 0 0;}#carryOver .headlineHeader{border:none;}.nextItem{display:-moz-inline-stack;display:inline-block;line-height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat right -540px;padding-right:20px;padding-left:4px;}.previousItem{display:-moz-inline-stack;display:inline-block;line-height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -520px;padding-left:20px;}#dedupSummary{padding:4px 0 0 4px;}#carryOver .headlineHeader span,#carryOver .headlineHeader b,#carryOver .headlineHeader a{display:-moz-inline-stack;display:inline-block;line-height:20px;}#carryOver .headlineHeader #carryOverCount{font-weight:bold;}#carryOverBtn{width:20px;height:20px;background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat 0 -460px;cursor:pointer;}.carryOverOpen #carryOverBtn{background-position:0 -420px;}#carryOver #carryOverBtn span{visibility:hidden;}#carryOverHeadlines{display:none;}.carryOverOpen #carryOverHeadlines{display:block;overflow:auto;border-bottom:1px solid #ccc;}a.carryOverRmv,a.carryOverRmv:visited{color:Red;font-size:14px;font-weight:600;line-height:13px;text-decoration:none;}.saveHeadlines #carryOverHeadlines{display:block!important;}#headlines{overflow:visible;_width:99%;}#headlines{overflow:auto;}.headline a{color:#007EC5;padding-bottom:2px;text-decoration:none;}#headlines a b,.headlines a b,#headlines .caHeadline,#headlines .bgHeadline,#headlines .caHeadline,#headlines .zhtwHeadline,#headlines .zhcnHeadline,#headlines .csHeadline,#headlines .daHeadline,#headlines .nlHeadline,#headlines .enHeadline,#headlines .fiHeadline,#headlines .frHeadline,#headlines .deHeadline,#headlines .huHeadline,#headlines .itHeadline,#headlines .jaHeadline,#headlines .noHeadline,#headlines .plHeadline,#headlines .ptHeadline,#headlines .ruHeadline,#headlines .skHeadline,#headlines .esHeadline,#headlines .svHeadline,#headlines .trHeadline,#headlines .koHeadline,#headlines .idHeadline,#headlines .msHeadline,#headlines .arHeadline{font-weight:bold;}.headline .leadFields{color:#888;font-size:.9em;}.headline .leadFields a{font-weight:normal!important;}.headline .snippet{color:#333;}.enHeadline{font-weight:bold;}.dedupHeadlines{padding:5px 5px 7px;}.mnuBtn,.mnuBtnOpen{color:#666;background-color:#F0F0F0;border:1px solid #D1D1D1;border-right-color:#393939;border-bottom-color:#393939;}.mnuBtn,.mnuBtnOpen{cursor:pointer;}.mnuBtnOpen span{font-size:10px;padding:0 3px;}.mnuBtn span{font-size:10px;padding:0 2px;}body.headlinesView #articleFrame,body.articleView #headlineFrame{float:none;display:none;}#articleFrame{padding:10px;}#articleFrame{border-right:solid 3px #EEE;border-bottom:solid 3px #EEE;}#articleFrame{border:none;}#articleFrame,body.framed #articleFrame,body.articleView #articleFrame{padding:0 1px 5px 2px;}#adFrameDiv{padding-top:20px;text-align:center;}.articleHref{line-height:1px;}.articleHeader{margin:0;padding:0 2px 2px 3px;}.articleHeader{margin:0;padding:7px;background-color:#E4E4E4;}.emg_speaker_button_span{position:relative;margin:0 0 0 5px;}.emg_speaker_attribution_cntr{position:relative;color:#999;}div.article{padding:0 10px;}div.article p{margin:1em 0;}.article #hd{color:#333;font:1.8em Arial,Helvetica,sans-serif;margin-bottom:2px;}.article #hd a{color:#007ec5;}.article .author{color:#333;margin-bottom:5px;}.article .srcLogo{border:0;}.article .articleParagraph{color:#333;margin-top:5px;}.headerTd{background:#efefef;padding:2px;}div.tabcontent{padding:5px 5px 20px;background:#f4fafe;}div.tabcontent td{padding:0 10px 0 0;}#navtab table tr #tabselected,#navtab table tr #tabselected td{background:#f4fafe;}#navtab table tr td table{cursor:pointer;}.menulist{display:-moz-inline-stack;display:inline-block;height:26px;padding:2px 0;float:left;}.menulist li{float:left;display:-moz-inline-stack;display:inline-block;width:26px;margin-right:2px;position:relative;}.menulist li .ppsBtn{display:block;text-indent:-9999px;font-size:.1em;width:26px;height:26px;background: transparent url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat 0 0;}.menulist li.ppsview .ppsBtn{background-position:0 0;}.menulist li.ppsemail .ppsBtn{background-position:-26px 0;}.menulist li.ppsprint .ppsBtn{background-position:-52px 0;}.menulist li.ppssave .ppsBtn{background-position:-78px 0;}.menulist li.ppsbriefcase .ppsBtn{background-position:-104px 0;}.menulist li.ppsrtf .ppsBtn{background-position:-156px 0;}.menulist li.ppspdf .ppsBtn{background-position:-130px 0;}.menulist li.ppsxml .ppsBtn{background-position:-182px 0;}.menulist li.ppsnewsletter .ppsBtn{background-position:-208px 0;}.menulist li.ppsquestion .ppsBtn{background-position:-234px 0;}.menulist li.ppclipboard .ppsBtn{background-position:-312px 0;}.menulist li.ppsdeleteselected .ppsBtn{background-position:-364px 0;}.menulist li.ppsview .ppsBtn:hover{background-position:0 -26px;}.menulist li.ppsemail .ppsBtn:hover{background-position:-26px -26px;}.menulist li.ppsprint .ppsBtn:hover{background-position:-52px -26px;}.menulist li.ppssave .ppsBtn:hover{background-position:-78px -26px;}.menulist li.ppsbriefcase .ppsBtn:hover{background-position:-104px -26px;}.menulist li.ppsrtf .ppsBtn:hover{background-position:-156px -26px;}.menulist li.ppspdf .ppsBtn:hover{background-position:-130px -26px;}.menulist li.ppsxml .ppsBtn:hover{background-position:-182px -26px;}.menulist li.ppsnewsletter .ppsBtn:hover{background-position:-208px -26px;}.menulist li.ppsquestion .ppsBtn:hover{background-position:-234px -26px;}.menulist li.ppclipboard .ppsBtn:hover{background-position:-312px -26px;}.menulist li.ppsdeleteselected .ppsBtn:hover{background-position:-364px -26px;}.menulist li.ppsview .ppsBtn.active:hover,.menulist li.ppsview .ppsBtn.active{background-position:0 -52px;}.menulist li.ppsemail .ppsBtn.active:hover,.menulist li.ppsemail .ppsBtn.active{background-position:-26px -52px;}.menulist li.ppsprint .ppsBtn.active:hover,.menulist li.ppsprint .ppsBtn.active{background-position:-52px -52px;}.menulist li.ppssave .ppsBtn.active:hover,.menulist li.ppssave .ppsBtn.active{background-position:-78px -52px;}.menulist li.ppsbriefcase .ppsBtn.active:hover,.menulist li.ppsbriefcase .ppsBtn.active{background-position:-104px -52px;}.menulist li.ppsrtf .ppsBtn.active:hover,.menulist li.ppsrtf .ppsBtn.active{background-position:-156px -52px;}.menulist li.ppspdf .ppsBtn.active:hover,.menulist li.ppspdf .ppsBtn.active{background-position:-130px -52px;}.menulist li.ppsxml .ppsBtn.active:hover,.menulist li.ppsxml .ppsBtn.active{background-position:-182px -52px;}.menulist li.ppsnewsletter .ppsBtn.active:hover,.menulist li.ppsnewsletter .ppsBtn.active{background-position:-208px -52px;}.menulist li.ppsquestion .ppsBtn.active:hover,.menulist li.ppsquestion .ppsBtn.active{background-position:-234px -52px;}.menulist li.ppclipboard .ppsBtn.active:hover,.menulist li.ppclipboard .ppsBtn.active{background-position:-312px -52px;}.menulist li.ppsdeleteselected .ppsBtn.active:hover,.menulist li.ppsdeleteselected .ppsBtn.active{background-position:-364px -52px;}.menulist li ul{display:none;}.mentionedLabelOff{display:none;}.firstRow{color:#FFF;font:bold 1.2em Arial,Helvetica,sans-serif;background-color:#666!important;padding:8px!important;}.even,.even td{background-color:#efefef;}.odd,.odd td{background-color:#FFF;}#framesLink,#noFramesLink{float:right;display:block;text-indent:-9999px;font-size:.1em;height:26px;width:26px;margin:2px 0 0 2px;background: transparent url('../img/facelift/resultsIconSprite.png?42.27.0')  no-repeat 0 0;text-decoration:none;}#framesLink{background-position:-260px 0;}#noFramesLink{background-position:-286px 0;}#framesLink:hover{background-position:-260px -26px;text-decoration:none;}#noFramesLink:hover{background-position:-286px -26px;text-decoration:none;}#framesLink.active:hover,#framesLink.active{background-position:-260px -52px;}#noFramesLink.active:hover,#noFramesLink.active{background-position:-286px -52px;}.controlsDiv:after,.frames:after,.actions:after,.resultPagination:after,.postProcessing:after,.presentationToggle:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.controlsDiv,.frames,.actions,.resultPagination,.postProcessing,.presentationToggle,.clearFix{zoom:1;}* html .controlsDiv,* html .frames,* html .actions,* html .resultPagination,* html .postProcessing,* html .presentationToggle,* html .clearFix{height:1%;}.headlineOptions{background-color:#e4e4e4;padding:2px 0;background-color:#e4e4e4;z-index:400;height:36px;}.headlineSort{float:left;display:-moz-inline-stack;display:inline-block;height:20px;vertical-align:middle;padding:5px;}.headlineDups{float:left;display:-moz-inline-stack;display:inline-block;height:20px;vertical-align:middle;padding:5px;}.headlineViewAs{text-align:left;position:relative;display:-moz-inline-stack;display:inline-block;vertical-align:middle;margin:4px 0 0;z-index:405;cursor:pointer;}.headlineViewAs a{display:block;padding:4px;}.headlineOptionsRight .open a,.headlineViewAs a:hover{background-color:#ccc;}.headlineViewAs .viewAs{display:block;padding:0 5px;line-height:20px;}.headlineViewAs .viewAs:hover,.open .viewAs{background-color:#d4d4d4;}.headlineViewAs .viewAsMenu{display:none;width:300px;position:absolute;top:22px;right:0;background-color:#fff;border:1px solid #ccc;z-index:406;}.open .viewAsMenu{display:block;}.headlineViewAs .optionList{height:200px;overflow:auto;background:#fff;z-index:751;}.headlineOptionsRight .open .optionList li a{display:block;padding:2px 5px;background-color:#fff;}* html .headlineOptionsRight .open .optionList li a{display:inline-block;width:100%;}.headlineOptionsRight .open .optionList li a:hover{background-color:#ffffe3;text-decoration:none;}.headlineViewAs .createNewView{margin:0 3px;padding:5px 0;border-top:1px solid #ccc;z-index:751;}.headlineOptionsRight .open .createNewView a{display:inline;color:#666;padding:0;background:none;}.headlineOptionsRight .open .createNewView a:hover{color:#55b0eb;background:none;}.headlineOptions input,.headlineOptions select{line-height:20px;}.buttons:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.buttons,.clearFix{zoom:1;}* html .buttons,* html .clearFix{height:1%;}.buttons{list-style:none;margin:0;padding:0;white-space:nowrap;}.buttons .btn{float:left;position:relative;padding-left:10px;}.buttons .btn .prettyBtn{height:23px;line-height:23px;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;padding-left:11px;cursor:pointer;padding-top:0;padding-bottom:0;}.buttons .btn .prettyBtn span{display:block;height:23px;line-height:23px;color:#fff;background-color:transparent;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;background-repeat:no-repeat;cursor:pointer;}.buttons .btn .prettyBtn{background-position:0 -647px;}.buttons .btn .prettyBtn span{background-position:right -671px;padding:0 15px 0 4px;}.buttons .btn .primaryBtnRight{background-position:0 -257px;}.buttons .btn .primaryBtnRight span{background-position:right -281px;padding:0 22px 0 4px;}.buttons .btn .primaryBtnLeft{background-position:right -744px;padding:0 11px 0 0;}.buttons .btn .primaryBtnLeft span{background-position:0 -768px;padding:0 4px 0 22px;}.buttons .btn .secondaryBtn{background-position:0 -165px;}.buttons .btn .secondaryBtn span{background-position:right -188px;padding:0 15px 0 4px;}.buttons .btn .disabled,.buttons .btn .tertiaryBtn{background-position:0 -353px;}.buttons .btn .disabled{cursor:default;}.buttons .btn .disabled span,.buttons .btn .tertiaryBtn span{color:#999;background-position:right -377px;padding:0 15px 0 4px;}.buttons .btn .disabled span{cursor:default;}.buttons .over .prettyBtn{background-position:0 -695px;}.buttons .over .prettyBtn span{background-position:right -719px;}.buttons .over .primaryBtnRight{background-position:0 -305px;}.buttons .over .primaryBtnRight span{background-position:right -329px;}.buttons .over .primaryBtnLeft{background-position:right -792px;}.buttons .over .primaryBtnLeft span{background-position:0 -816px;}.buttons .over .secondaryBtn{background-position:0 -211px;}.buttons .over .secondaryBtn span{background-position:right -234px;}.buttons .over .tertiaryBtn{background-position:0 -165px;}.buttons .over .tertiaryBtn span{color:#fff;background-position:right -188px;}.buttons .standardBtn{position:absolute;top:0;left:0;right:0;bottom:0;cursor:pointer;}.buttons .standardBtn{opacity:0;filter:alpha(opacity=0);}* html .buttons .btn .prettyBtn{display:inline;}* html .buttons .btn .prettyBtn span{display:inline-block;}ul.floatRight{float:right!important;}.modalHeader:after,.modalFooter:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.modalHeader,.modalFooter,.clearFix{zoom:1;}* html .modalHeader,* html .modalFooter,* html .clearFix{height:1%;}.modal{padding:10px;background-color:#fff;}.modalHeader{padding:10px;background-color:#efefef;}.modalHeader .modalTitle{font-size:1.2em;font-weight:bold;}.modalContent{padding:10px;}.modalFooter{padding:0 10px;}.modalFooter .buttons{float:right;display:-moz-inline-stack;display:inline-block;}#emailModal .modalHeader .supportLink{float:right;display:-moz-inline-stack;display:inline-block;}#emailModal .modalContent .disclaimer{color:#afafaf;margin-bottom:5px;}#emailModal .modalContent .disclaimer a{color:#007ec5;}#emailModal .emailOptions table{width:100%;}#emailModal .emailOptions table td{vertical-align:top;padding:3px;}#emailModal .emailOptions table td .emailUpdate{color:#007ec5;}#emailModal .emailOptions table td.label{text-align:right;}#emailModal .emailOptions table td label{margin:0 5px 0 2px;}.appliedFilters:after,.DJIIFilterList:after,.connectionAndPillWrap:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.appliedFilters,.DJIIFilterList,.connectionAndPillWrap,.clearFix{zoom:1;}* html .appliedFilters,* html .DJIIFilterList,* html .connectionAndPillWrap,* html .clearFix{height:1%;}.pillOptionsList{cursor:pointer;}.filterText{white-space:nowrap;}.DJIIFilterList li{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-bottom:3px;}#ml_sc_edit_selected_list .DJIIFilterList li{clear:left;}#sccompanylist .DJIIFilterList li{clear:left;}.connectionAndPillWrap .filterConnection,.connectionAndPillWrap .filterPillWrap,.connectionAndPillWrap .filterType{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-right:5px;}.DJIIFilterList .pill,.DJIIFilterList .pill .filterText,.DJIIFilterList .pillNoMenu,.DJIIFilterList .pillNoMenu .filterText,.DJIIFilterList .filterConnection,.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .pillOption,.pillOptionsList .pillOption span{background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;background-repeat:no-repeat;}.DJIIFilterList .pill{background-position:0 -402px;}.DJIIFilterList .pill .filterText{background-position:right -419px;}.DJIIFilterList .pillNoMenu{background-position:0 -577px;}.DJIIFilterList .pillNoMenu .filterText{background-position:right -594px;}.DJIIFilterList .filterConnection,.pillOptionsList .or,.pillOptionsList .not,.pillOptionsList .and{background-position:0 -472px;}.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span{background-position:right -489px;}.pillOptionsList .remove{background-position:0 -542px;}.pillOptionsList .remove span{background-position:right -559px;}.DJIIFilterList .pill:hover,.DJIIFilterList .active .pill{background-position:0 -437px;}.DJIIFilterList .pill:hover .filterText,.DJIIFilterList .active .pill .filterText{background-position:right -454px;}.DJIIFilterList .pillNoMenu:hover,.DJIIFilterList .active .pillNoMenu{background-position:0 -612px;}.DJIIFilterList .pillNoMenu:hover .filterText,.DJIIFilterList .active .pillNoMenu .filterText{background-position:right -629px;}.pillOptionsList .or:hover,.pillOptionsList .not:hover,.pillOptionsList .and:hover,.pillOptionsList .remove:hover{background-position:0 -507px;}.pillOptionsList .or:hover span,.pillOptionsList .not:hover span,.pillOptionsList .and:hover span,.pillOptionsList .remove:hover span{color:#fff;background-position:right -524px;}.pillOptionsList .or,.pillOptionsList .not,.pillOptionsList .and,.pillOptionsList .remove{min-width:100px;height:17px;line-height:17px;padding:0 0 0 6px;}* html .pillOptionsList .or,* html .pillOptionsList .not,* html .pillOptionsList .and,* html .pillOptionsList .remove{width:100px;}.DJIIFilterList .pill,.DJIIFilterList .pillNoMenu,.DJIIFilterList .filterConnection{display:-moz-inline-stack;display:inline-block;float:left;height:17px;line-height:17px;padding:0 0 0 6px;}.DJIIFilterList .pill .filterText,.DJIIFilterList .pillNoMenu .filterText,.DJIIFilterList .filterConnection .connectionText,.DJIIFilterList .filterConnection .connectionText,.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span,.pillOptionsList .remove span{display:-moz-inline-stack;display:inline-block;height:17px;color:#333;line-height:17px;text-align:center;padding:0 10px 0 4px;}.connectionTextOr,.connectionTextAnd{cursor:default;}#coLst .connectionTextOr,#coLst .connectionTextAnd,#nsLst .connectionTextOr,#nsLst .connectionTextAnd,#inLst .connectionTextOr,#inLst .connectionTextAnd,#reLst .connectionTextOr,#reLst .connectionTextAnd{cursor:pointer!important;}.pillOptionsList .or span,.pillOptionsList .not span,.pillOptionsList .and span,.pillOptionsList .remove span{display:block;}.pillOptionsList .remove span{color:#fff;}.DJIIFilterList .pill .filterText{padding:0 20px 0 4px;}.active .pillOptionsList{display:block;position:absolute;top:17px;right:0;}.appliedFilters .label,.appliedFilters .DJIIFilterList{float:left;display:-moz-inline-stack;display:inline-block;margin-right:5px;}.appliedFilters .label{font-weight:bold;}.noFilterTextIn{background-position:right -593px!important;height:30px!important;}.floatLeft{float:left;}.floatRight{float:right;}.headlineOptionsLeft{float:left;display:-moz-inline-stack;display:inline-block;padding:0 0 0 10px;}.headlineOptionsLeft span{float:left;display:-moz-inline-stack;display:inline-block;padding:6px 0 0;margin:0 5px 0 0;}.headlineOptionsRight{float:right;display:-moz-inline-stack;display:inline-block;padding:0 10px 0 0;z-index:403;text-align:right;}.headlineOptionsRight span{position:relative;display:-moz-inline-stack;display:inline-block;z-index:749;margin:4px 0 0;vertical-align:middle;}.headlineOptionsRight span span,.headlineOptionsRight span span span{margin:0;}#mentionedLabel1{z-index:401;}#mentionedLabel1 div{z-index:402;}#mentionedLabel1 .postprocessinglinks{margin:2px 5px 0 5px;padding:0;}.clear{clear:both;}.marginLeft_0px{margin-left:0!important;}.paddingLeft_10px{padding-left:10px!important;}.headlines tr.over{background:#FFFFE3;}#directLinkBox .overlayfooter ul{float:right;}#directLinkBox td{padding:3px;}.overlaycontainer{font-family:Arial,Helvetica,sans-serif;font-size:12px;background:white;border:solid 1px silver;width:600px;margin:20px;position:relative;}.overlayrenamecontainer{font-family:Arial,Helvetica,sans-serif;font-size:12px;background:white;border:solid 1px silver;width:350px;height:120px;margin:20px;position:relative;}.overlayclose{background : url('../img/close.png?42.27.0')  no-repeat;_background : url('../img/close2.gif?42.27.0')  no-repeat!important;cursor:pointer;position:absolute;width:25px;height:25px;right:-15px;top:-15px;}* html .overlayclose{background : url('../img/close.gif?42.27.0')  no-repeat;}.overlayheader{font-family:Arial,Helvetica,sans-serif;font-size:12px;font-weight:bold;margin:10px;background:#4b4b4b;padding:7px;color:#fff;}.overlaybody{margin:10px;}.overlaytable{border-collapse:separate;border-spacing:5px;}.overlaytable td{vertical-align:middle;}.overlaytitle{width:120px;white-space:nowrap;}.overlayselect{border:solid 1px #ccc;width:300px;}.overlaycreatelist{border:solid 1px #ccc;width:296px;}.overlaylink{color:#309;cursor:pointer;padding-left:5px;padding-right:5px;}.overlaylinkdisable{color:#ccc;cursor:none;}.overlayline{margin-top:5px;margin-bottom:15px;border:solid 1px #ccc;}.overlaytext{border:solid 1px #ccc;width:300px;}.overlaysourcelist{height:160px;overflow:auto;}.overlayitem{border:solid 1px #FBE0A8;background:#FBE0A8;padding:2px 5px 2px 5px;margin-bottom:2px;}.overlayfooter{margin:10px;}.overlaytextbold{font-weight:bold;}.ceprogress{display:none;background-color:#fff;border:1px outset #ccc;font-family:Arial,Helvetica,sans-serif;font-size:11px;color:#000;-webkit-border-radius:3px;-moz-border-radius:3px;position:absolute;z-index:10006;width:140px;text-align:center;padding:5px;}.ceerror{color:#f00;}.overlaypillscontextmenu{position:absolute;display:none;z-index:10002;}#directLinkBox .overlayfooter{position:relative;}#directLinkBox{height:auto!important;}.resultsBar{padding-left:4px;}#mbBody .resultsBar{left:49px;position:absolute;}#editws #mbBody .resultsBar{left:inherit!important;position:inherit!important;top:inherit!important;}#editws #mbBody #selectAll{float:left;}#editws #mbBody #clearAll{float:left;}.search_autosuggest_over{background-color:#55B0EB!important;color:white;cursor:pointer;}.printheadline{color:#333;font:1.8em Arial,Helvetica,sans-serif;margin-bottom:2px;}.nomargin{margin:0!important;}.nopadding{padding:0!important;}.ea #contentWrapper{width:100%!important;}.ea #contentWrapper input,.ea #contentWrapper textarea{width:90%!important;}#trackHeads33 .alertsHeader{float:left;}#trackHeads33 table td{vertical-align:middle;}#trackHeads33 .alertsHeader #folderDDLabel{margin-right:5px;color:#333;font-size:1.2em;line-height:26px;}#trackHeads33 .alertsHeader .alertsList{margin-right:5px;}.searchOptions{float:right;display:inline-block;height:23px;}.searchOptions .editAlert,.searchOptions .changeAccess,.searchOptions .alertOptions{display:inline-block;line-height:26px;padding:0 3px;color:#333;}.searchOptions .alertOptions{color:#55B0EB;}.searchOptions .alertOptions a{display:inline-block;background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat right -417px;padding:0 20px 0 0;}.alertOptions{position:relative;}.alertOptionsMenu{display:none;}.open .alertOptionsMenu{display:block;height:175px;width:200px;position:absolute;top:23px;right:0;background-color:#fff;border:1px solid #ccc;}.xmlLinkWithIcon{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat -340px -3px;}.xmlLinkWithIcon:hover{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat -340px -29px;}.alertList{display:inline-block;height:20px;position:relative;margin:0 5px 0 0;z-index:100;}.alertListLink{display:inline-block;width:212px;color:#333;line-height:20px;background:#eee url(../img/facelift/facelift-icon-sprite.gif) no-repeat right -498px;padding:0 5px;}.open .alertListLink,.alertListLink:hover{background-color:#d7d7d7;}.alertListMenu{display:none;position:absolute;width:200px;background-color:#fff;border:1px solid #ccc;}.open .alertListMenu{display:block;left:0;top:20px;}.alertListMenu ul li{padding:0;}.alertListMenu ul li .alertTypeSectionHead{display:block;line-height:12px;padding:3px 5px;background-color:#f3f3f3;}.alertListMenu ul li a{display:block;color:#333;line-height:12px;padding:2px 5px 2px 25px;vertical-align:top;}.alertListMenu ul li a:hover{background-color:#dbeefc;}* html .alertListMenu ul li .alertTypeSectionHead,* html .alertListMenu ul li a{height:12px;}.hr{height:100px;}#emtRow td{height:1px;}.ceprogress,.confirmDialog,.messageDialog{background-color:#fff;border:1px solid #ccc;font-family:Arial,Helvetica,sans-serif;font-size:11px;font-weight:bold;color:#000;-webkit-border-radius:3px;-moz-border-radius:3px;position:absolute;text-align:center;padding:10px 30px 10px 30px;}.confirmDialog,.messageDialog{border:5px solid #555;padding:20px 30px 15px 30px;}.ceerror{color:#f00;}#messageDialogOk td{padding-top:15px;text-align:center;}#messageDialogOk td ul{width:50px;float:none!important;}#messageDialogOk .btn{margin-left:0;}#confirmDialogButtons td{padding-top:15px;text-align:center;}#confirmDialogButtons td ul{width:120px;float:none!important;}#confirmDialogButtons #confirmDialogYes{margin-left:0;}.modalPage{margin:0;}.modalPage #contentWrapper{padding:0;width:800px;}#bottomSaveCanc{padding-right:48px;}.foldersDeliveryOptions table{padding:10px;width:100%;}.foldersDeliveryOptions td{padding:5px;}.foldersDeliveryOptions .delMnu{height:552px;width:100%;}.foldersDeliveryOptions .botButtonWrap .buttons{width:100%;}.foldersDeliveryOptions #tdFirst{width:33%;}.foldersDeliveryOptions #tdSecond{width:20%;}.foldersDeliveryOptions #tdThird{width:39%;}.foldersDeliveryOptions .itemText{margin-top:0;}#topBox{background-color:#fff;}#bottomBox{background-color:#fff;}.foldersDeliveryOptions .buttons li{padding:10px;}.foldersDeliveryOptions .buttons .btn{float:none;}.foldersDeliveryOptions .modalCancel{bottom:0;cursor:pointer;left:0;opacity:0;position:absolute;right:0;top:0;}#trOne{border-left:1px solid #999;padding-left:0;padding-right:0;background:none repeat scroll 0 0 #EEE;}#trTwo{border-left:1px solid #999;padding-left:0;padding-right:0;background:none repeat scroll 0 0 #EEE;}#tdOne{border-left:1px solid #999;padding-left:0;padding-bottom:0;padding-right:0;border-bottom:1px solid #999;border-right:1px solid #999;}#tdZeroRightP{padding-right:0;border-right:1px solid #999;border-top:1px solid #999;}#tdZeroRightPEX{border-top:1px solid #999;}*#tdZeroRightPEX{*border-left:1pxsolid#999;}#tdZeroRightPNoT{padding-right:10px;border-right:1px solid #999;border-bottom:1px solid #999;}#tdZeroRightPNos{border-bottom:1px solid #999;}*#tdZeroRightPNos{*border-left:1pxsolid#999;}.menuSelected{background-color:#dbeefb!important;}.menuItemC{color:#000;margin-top:2px!important;float:left;text-decoration:none;margin-left:4px;}.foldersDeliveryOptions .mnuItm{padding-top:2px;padding-bottom:2px;margin-top:2px;float:left;text-decoration:none;margin-left:4px;background-color:transparent;border-color:#999;border-width:1px;z-index:800;}.delMnu li,.delMSel li,.delASel li{z-index:900;}.delMnu li a,.delMSel li a,.delASel li a{z-index:800;}#afternoonListC select{border:none;}#morningListC select{border:none;}.foldersDeliveryOptions .delMnu ul{margin:0 0 2px;z-index:1;}.folderClosed{cursor:pointer;z-index:800;height:20px;}.delMSel a:focus,.delMSel a:hover,.delASel a:focus,.delASel a:hover,.delMnu a:focus,.delMnu a:hover{color:#000;}.delMSel{overflow:auto;height:200px;}.delASel{overflow:auto;height:200px;}#morningListC{margin-top:-3px;}#afternoonListC{margin-top:-3px;}.dragSelected{background-color:#dbeefb;}.deliveryOptions{margin-bottom:20px;}.botButtonWrap{margin-left:0;}.foldersDeliveryOptions .buttons .btn .prettyBtn span{color:#FFF!important;cursor:pointer;text-align:center;}.foldersDeliveryOptions .orderUp{cursor:pointer;background : url('../img/up.png?42.27.0')  no-repeat;height:24px;width:24px;margin-bottom:5px;}.foldersDeliveryOptions .orderDown{cursor:pointer;background : url('../img/down.png?42.27.0')  no-repeat;height:24px;width:24px;}*.foldersDeliveryOptions .buttons .btn .prettyBtn span{*width:115px;*margin-right:0;}#dcSaveAuxCntr .buttons .btn .prettyBtn span{color:#FFF!important;cursor:pointer;text-align:center;}.modalPage .modalFooter .buttons{padding-left:0;float:left;}.modalPage #dcSaveEditCntrL1{float:left;width:196px;}.modalPage #dcSaveEditCntrL2{float:left;}.modalPage #dcSaveCreateCntrL1{float:left;margin-top:20px;width:196px;clear:both;}.modalPage #dcSaveCreateCntrL2{float:left;margin-left:-3px;margin-top:20px;width:250px;}.modalPage #dcSaveCreateCntrL3{float:left;margin-left:-3px;width:250px;margin-top:20px;}.modalPageTopContainer{width:700px;}.modalPage #dcSaveBodyCntr{float:left;position:relative;padding-bottom:20px;width:810px;}.modalPage #RnmLnk{margin-left:5px;margin-right:5px;}.modalPage #dcSaveAuxCntr{float:left;margin-bottom:20px;position:relative;width:100%;}.modalPage #dcSaveAuxCntr td{width:300px;padding-left:20px;padding-right:20px;padding-top:2px;padding-bottom:2px;}#dcSaveAuxCntr .mnuItm{padding-top:3px;padding-bottom:2px;}#dcSaveAuxCntr .mnuItmSelected{padding-top:2px;padding-bottom:2px;background-color:#dbeefb;border-top:1px solid #BABCD1;color:black;}.SSeleted,.CSeleted{padding-top:2px;padding-bottom:2px;background-color:#dbeefb;border-top:1px solid #BABCD1;color:black;}#dcSaveAuxCntr .buttons li{margin-top:30px;float:none;}#dcSaveAuxCntr .botButtonWrap{width:124px;}#dcSaveAuxCntr .botButtonWrap .buttons{width:115px;float:none;}.mnuItmAdded{border:1px solid #BABCD1;background-color:#dbeefb!important;}#leftSControl,#rightSControl{padding-top:2px;padding-bottom:2px;margin-top:2px;background-color:transparent;height:400px;border:1px solid #BABCD1;width:265px;}#leftSControl .mnuItm,#rightSControl .mnuItm{background-color:transparent;margin-left:4px;}#leftSControl .folderClosed,#rightSControl .folderClosed{padding:2px;}#leftSControl .menuItemC,#rightSControl .menuItemC{margin-top:0!important;}#ContainerEAT p.button-row{text-align:left;}#ContainerEAT td{padding:3px;}#ContainerEAT .buttons .minorButton{opacity:0;bottom:0;cursor:pointer;left:0;position:absolute;right:0;top:0;}#ContainerEAT .botButtonWrap{float:none;clear:both;}#ContainerEAT .botButtonWrap .buttons{float:none;clear:both;}#ContainerEAT{clear:both;margin-bottom:-10px;}#sendDivE{margin-left:-10px;}#ContainerEAT .buttons .majorButton{opacity:0;bottom:0;cursor:pointer;left:0;position:absolute;right:0;top:0;}#emailSentC{width:520px;}#emailSentC ul{float:right;}#messageTop{margin-top:20px;margin-bottom:40px;}.lTD{text-align:right!important;width:170px;}#idNoResults{margin-bottom:40px;margin-top:20px;}#widgetFolderContainer div.tip{margin:10px 0 10px 5px;}.margin_10px{margin:10px;}.marginTop_10px{margin-top:10px;}.marginBottom_10px{margin-bottom:10px;}.marginRight_10px{margin-right:10px;}.marginTop_5px{margin-top:5px;}.marginBottom_5px{margin-bottom:5px;}.padding_10px{padding:10px;}.paddingBottom_15px{padding-bottom:15px;}.paddingBottom_10px{padding-bottom:10px;}.paddingBottom_0px{padding-bottom:0!important;}.paddingTop_10px{padding-top:10px;}.paddingRight_10px{padding-right:10px;}.paddingLeft_10px{padding-left:10px;}.paddingLeft_0px{padding-left:0!important;}.paddingLeft_5px{padding-left:5px;}.paddingRight_5px{padding-right:5px;}.txtBold{font-weight:bold;}.txtLight{color:#aaa;}.txtRight{text-align:right;}#articleViewAs ul li a.selected{background-color:#FFFFE3;}.overlaybody .close{display:none;}.articleParagraph b{font-weight:bold!important;}.odeArticle Table{padding:5px;}.odeArticle td{padding:5px;}.odeArticle p{margin-bottom:10px;}#SaveButCreate{margin-top:5px;margin-bottom:-10px;}#articleViewAs .pnlTab{width:100px;}#articleViewAs .pnlTabOpen{width:115px;}.cssQuotePage #contentLeft{float:left;}.cssQuotePage #inpfid{float:left;width:170px;}body.cssQuotePage #contentLeft,body.cssQuotePage #contentLeft div.module{width:320px;}.cssQuotePage #contentRight{margin-left:325px;height:100%;}.cssQuotePage b{font-size:100%;font-weight:bold;position:relative;top:-1px;}.cssQuotePage td,.cssQuotePage th{font-size:100%;}.cssQuotePage .title td{padding:5px;}#ml_main .buttons .btn .prettyBtn span{text-align:center;}.cssWidth2P{width:2%;background:none repeat scroll 0 0 #E8E8E8;}.cssWidth38P{width:38%;}.cssWidth60P{width:60%;}.css_ml_cellTD1{width:40%;}.css_ml_cellTD2{width:30%;}.css_ml_cellTD3{width:30%;}.ml_css_section{padding-bottom:10px;}#ml_sc_table1,#ml_sc_table2{width:100%;}#ml_co_table1,#ml_co_table2{width:100%;}#ml_qo_table1,#ml_qo_table2{width:100%;}#ml_sc_table2,#ml_co_table2,#ml_qo_table2{background-color:#FFF;border:1px solid #EFEFEF;}#ml_sc_table2 td,#ml_co_table2 td,#ml_qo_table2 td{border-bottom:1px solid #EFEFEF;font-size:10px;font-weight:normal;height:30px;padding:0;text-align:left;vertical-align:middle;}.css_ml_titlerow{padding:5px;background:#e8e8e8;}.css_ml_title{cursor:pointer;font-weight:bold;}.css_ml_header{padding:10px;background:#f5f5f5;font-weight:bold;}.css_ml_toggle{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -40px;height:18px;width:15px;cursor:pointer;}.css_ml_toggle.close{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -20px;}.css_ml_message{text-align:center;}.css_ml_cell{padding:8px;border-bottom:solid 1px #f5f5f5;border-left:solid 1px #f5f5f5;}.css_ml_row_hover{background:#CDE7FC;}.css_ml_cell_last{border-right:solid 1px #f5f5f5;}.css_ml_link{padding-left:10px;color:#55b0eb;cursor:pointer;}.css_ml_link:hover{padding-left:10px;color:#55b0eb;}.css_ml_separator{padding-left:10px;color:#ccc;}.overlaylist{height:90px;overflow:auto;border:solid 1px silver;overflow:auto;margin-bottom:5px;padding:5px;}.overlaybar{margin-bottom:5px;}.overlaysearchbutton{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -80px;width:20px;height:20px;margin-left:5px;cursor:pointer;}.appliedFilters:after,.DJIIFilterList:after,.connectionAndPillWrap:after,.clearFix:after{content:".";display:block;height:0;clear:both;visibility:hidden;}.appliedFilters,.DJIIFilterList,.connectionAndPillWrap,.clearFix{zoom:1;}* html .appliedFilters,* html .DJIIFilterList,* html .connectionAndPillWrap,* html .clearFix{height:1%;}.DJIIFilterList li{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-bottom:3px;}.connectionAndPillWrap .filterConnection,.connectionAndPillWrap .filterPillWrap,.connectionAndPillWrap .filterType{float:left;position:relative;display:-moz-inline-stack;display:inline-block;margin-right:5px;}#ml_co_searchnameonly{margin-right:10px;}.lf{cursor:pointer;}.spacer_10px{height:10px;overflow:hidden;}.dj_tophat-firstview{background : url('../img/tile_background.png?42.27.0')  repeat-x scroll 0 0 transparent;font-family:arial,sans-serif;position:relative;}.dj_tophat-firstview .dj_header-panel .wrap{margin:0 auto;padding-left:40px;padding-right:40px;}.dj_tophat-firstview .dj_information .wrap{background:none;height:194px;margin:0 auto;width:1025px;}.dj_tophat-firstview .dj_header-panel{background:none repeat scroll 0 0 #424242;border-bottom:1px solid #535353;height:30px;}.dj_tophat-firstview .dj_header-panel h1{color:white;float:left;font-size:12px;margin:8px 0 0;padding:0;cursor:pointer;font-weight:bold;}.dj_tophat-firstview .dj_header-panel h2.disable{background : url('../img/close_button.png?42.27.0')  no-repeat scroll right center transparent;color:#999;cursor:pointer;float:right;font-size:12px;margin-top:8px;padding:0 30px 0 0;}.dj_tophat-firstview .dj_information{background : url('../img/grid_background.png?42.27.0')  no-repeat scroll center center transparent;display:block;height:196px;}.dj_tophat-firstview .dj_information img{float:left;margin-top:10px;}.dj_tophat-firstview .dj_information h3.dj_beta{background : url('../img/beta_tag.png?42.27.0')  no-repeat scroll right top transparent;color:white;display:inline;font-size:26px;font-weight:normal;margin:0;padding:0 40px 0 0;text-shadow:0 0 5px #000;}.dj_tophat-firstview .dj_information .dj_text{float:right;margin-top:25px;width:630px;}.dj_tophat-firstview .dj_information p{color:white;font-size:16px;line-height:1.5;margin:10px 0 0;padding:0;width:400px;}.dj_tophat-firstview .dj_information ul.dj_next{float:right;margin-right:20px;}.dj_tophat-firstview .dj_information ul.dj_next li{display:inline;list-style-type:none;margin-right:20px;}.dj_tophat-firstview .dj_information ul.dj_next li a{color:white;font-size:12px;font-weight:bold;text-decoration:none;}.dj_tophat-firstview .dj_information ul.dj_next li.get_started a{-moz-border-radius:10px 10px 10px 10px;-webkit-border-radius:10px 10px 10px 10px;border-radius:10px 10px 10px 10px;background:none repeat scroll 0 0 #93BE4E;padding:5px 10px;}.dj_tophat-firstview .dj_information ul.dj_next li.later a{color:#CCC;}.cellPadding_3px td{padding:3px;}.cellPadding_5px td{padding:5px;}.cellValignTop td{vertical-align:top;}.cssArticleO .DJIIFilterList .pill .filterText{background-position:right -594px;}.cssArticleO .DJIIFilterList .pill:hover,.DJIIFilterList .active .pill{background-position:0 -402px;}.displayBlock{display:block;}.groupAdmin table.searchoptions td.Off{border:1px solid #fff!important;padding:1px!important;}#ml_sc_edit1overlay{height:470px;width:600px;}.admnSSID #ssidTable{background-color:#b1babb;}.pnlMnu li ul{margin:0 0 0 20px;padding:0;}.pnlMnu li{margin:0;padding:2px 0;}.pnlMnu ul{list-style-type:none;margin:0;padding:0 0 5px;}#dateAndDupRow .sbSubmit .floatRight{padding-right:10px;}#npModal .npMnu,#npModal .npMnu2{padding:0;}#npModal .npMnu ul{margin:0;}#npModal .mnuItm{margin-left:5px;}#npModal .mnuItm{background-color:transparent;}#npModal .mnuItmSelected{background-color:#DBEEFB!important;border:1px solid #BABCD1!important;}.addRemBtn .buttons .btn{float:none;margin-top:10px;}#npModal #issmd{margin-left:25px;}#npModal #ifmd{margin-left:25px;}#npModal #isosmd{margin-left:25px;}#npModal .svCBtn{float:right;width:200px;}#npModal .npMnu li{padding-top:2px;padding-bottom:2px;}#npModal .npMnu li ul{margin-left:17px;}#npModal .folderClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -134px -94px;margin-left:5px;}.sharedClosed{height:20px;}#npModal .sharedClosed .itemIcon{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat -104px -110px;margin-left:5px;}#npModal .buttons .btn .primaryBtnLeft span{text-align:center;}.norecords div{padding-left:25px;}#siteAlertMain .close a{background: transparent url('../img/close_icon.gif?42.27.0')  no-repeat 0 0;height:17px;position:absolute;right:18px;top:5px;width:17px;}.overlaycontainer #d1cnt span{display:inline-block;position:static;}.mnuBtnOff span{display:inline-block;position:relative!important;top:-5px!important;}#ml_sc_list .mnuBtnOff span{display:inline-block!important;position:static!important;}#ml_sc_list .mnuBtnOff{display:inline-block!important;position:static!important;}.overlaylist li ul li{margin-left:10px;}#ml_sc_editoverlay .searchBuilderFilters{position:relative;}#ml_sc_editoverlay .overlaylist{position:relative;}.btnWidth{width:130px!important;float:left;margin-bottom:10px;}.cqscTopDiv{margin:5px;padding-top:20px;}.cqscCodingS{float:left;width:110px;}.cqscSearchText{float:left;margin-left:10px;}.cqscBtnSear{float:left;width:100px;}.cqscSelectFromList{float:left;margin-top:10px;width:100px;}.cqscCompanyListControl{float:left;margin-right:10px;margin-top:10px;width:180px;}.cqscSelectList{float:left;width:110px;margin-top:10px;}.bdbulkmn{width:auto!important;}.tableCellPadding_5px td{padding:5px;}.tableCellPadding_3px td{padding:3px;}.tableCellPadding_5px th{padding:10px;}.actionNodes span{display:inline-block;}.quoteOuterD{height:340px;}.ssCOut{height:30px;}.ssC1but{width:100px;height:30px;}.ssC2but{height:30px;}#scl{width:180px;}#qicl{width:180px;}.mdsChartTitle{padding-top:10px;}.entrie table tbody tr th{padding-top:10px;padding-bottom:10px;font-weight:bold;}.entrie table tbody tr td{padding-top:5px;padding-bottom:5px;}#edittable td{padding:5px;align:center;}#edittable th{padding:5px;}#addtable td{padding-top:5px;padding-bottom:5px;}#addtable th{padding:5px;}.margin5PX{padding:5px;}.greyTbl th{padding:10px;}.width200PX{width:200px;}.width150PX{width:150px;}.width100PX{width:100px;}#ttDiv .btnTTC{margin-top:10px;}.cssPaddingRight10px{padding-right:10px;}.tt_mnuItmSelected{background-color:#DBEEFB!important;border:1px solid #BABCD1!important;}.pnlLst{vertical-align:top;height:22px;}.height80PX{height:115px!important;}.cssArticleO{height:182px;}#gl-navBottom{min-width:960px!important;}#gl-navBottomMiddle{min-width:960px!important;}* html .cssIE6MinWidth{*padding-left:1100px!important;*height:1px!important;}* html .cssIE6MinWidthAdj{*margin-left:-1100px!important;*position:relative!important;*height:1px!important;}* html .cssIE6MinWidthAdjLay{*height:1px!important;}.sbinfoIcon{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -304px transparent;display:inline-block;width:20px;}.addFIICodeIcon{background : url('../img/facelift/facelift-icon-sprite.png?42.27.0')  no-repeat scroll 0 -144px transparent;display:inline-block;width:20px;}.searchoptions td a{color:#906;padding:2px 2px 2px 5px;}.searchoptions .searchContainer td{color:#000;font-weight:bold;border:0 solid white;}.searchoptions td{padding:3px;background-color:#EAEBF5;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-decoration:none;height:13px;border:1px solid white;}.searchoptions tr{color:#000;}.searchoptions #Header td{padding:3px;background-color:#999!important;color:#fff;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-decoration:none;font-weight:bold;height:13px;border:1px solid white;}.searchoptions #Header tr{color:#000;}#NoBody td{padding:2px;background-color:white;color:white;}div.content,div.exContent,div.contentWithTabs,div.scrContent{zoom:1;}.searchContainer{background : url('../img/bar_lt_news.gif?42.27.0')  no-repeat scroll;color:#000;font-family:Arial,Helvetica,sans-serif;text-decoration:none;margin-bottom:10px;padding-right:10px;position:relative;vertical-align:middle;zoom:1;}.searchContainer td{padding:3px;color:#000;border:none;}#npModal .subTitle{color:#FFF;}.overlaylist{position:relative;}.overlaylist #d1cnt{overflow:hidden;}.arHeadline{direction:rtl;unicode-bidi:embed;}.arsnippet{direction:rtl;unicode-bidi:embed;}.arTextAlign{text-align:left;}.sssuggest{padding-top:5px;margin:10px 0 0 37px;font:arial 12px;color:#666;border-top:#e6e7e8 1px solid;}#ssp{display:none;}#sspDiv{_width:560px;}.sspDesc{padding:0 0 10px 0;width:470px;margin:0 40px 0 40px;}.sspDesc1{text-align:center;padding:15px 0 20px 0;font-size:18px;font-weight:bold;}.sspDesc2{font-size:12px;}.sspDesc2 ul{list-style-type:none;padding:0;margin:0;}.sspDesc2 li{padding-bottom:10px;}.sspInputWrapper{border:1px solid #8c92b1;padding:10px 10px 10px 10px;margin-left:40px;margin-right:40px;white-space:nowrap;background-color:#e2e6f3;}.ssatx{font-size:16px;border:1px solid #d6d6d6;}.sspNoThanksDiv{padding:15px 0 15px 0;text-align:right;margin-left:20px;margin-right:20px;}#sspDiv div.floatRight{display:none;}#sspDiv,#sspDiv .popupHdr{background-color:#E1E1E1;}#sspBody{background-color:#EFEFEF;}.dj_emg_autosuggest_odd{background-color:#EEEDED!important;}.dj_emg_autosuggest_even{background-color:#FFF!important;}.dj_emg_autosuggest_over{background-color:#d8e2e5!important;color:Black!important;}.dj_emg_autosuggest_results{background-color:#FFF;z-index:100000!important;width:600px!important;}.scResultPopup{width:600px!important;}a.ac_info{background-image : url('../img/sbInfo.gif?42.27.0') !important;}a.ac_promote{background-image : url('../img/sbUpArrow.gif?42.27.0') !important;display:block!important;}.clsScrFrm a.ac_promote{background-image : url('../img/sbUpArrow.gif?42.27.0') !important;display:none!important;}#bkScrn{position:absolute;left:0;top:0;background:#A5A5A5;display:none;z-index:998;}a.ac_not{background: transparent url('../img/exclude.png?42.27.0')  no-repeat scroll center center!important;}* html #gl-navTop #gl-navTopLeft h1{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat 0 -209px;}* html #gl-navTopRightUl li#mbrightddtbm1,* html #gl-navTopRightUl li#mbrightddtbm0{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat right -4px;}* html #gl-navTopRightUl li#myDJFmenu{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat left -64px;}* html #gl-navTopRightUl li .settingsToolsDrop div .sectionTitle{background-image : url('../img/facelift/facelift-icon-sprite-darkgrayMatte.gif?42.27.0') ;}* html #gl-navBottom{background: transparent url('../img/facelift/facelift-repeatingBG-sprite.gif?42.27.0')  repeat-x 0 0;}* html #gl-navBottomMiddle{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -132px;}* html #gl-navBottomMiddle ul#menulist{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 -99px;}* html #gl-navBottomMiddle ul li.selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 0;}* html #gl-navBottomMiddle ul li.selected a{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat right -66px;}* html #gl-navBottomMiddle ul li.first-selected{background: transparent url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0')  no-repeat 0 -33px;}* html .footerBrand{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat scroll 0 -40px;}* html .ftright{background: transparent url('../img/facelift/facelift-brand-sprite.gif?42.27.0')  no-repeat scroll 0 -80px;}* html .fcsclose,* html .fcsopen{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}* html .pnlTab .pnlTabArrow{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -20px;}* html .pnlTabOpen .pnlTabArrow{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -40px;}* html .lkpBar .lkpBtn{background: transparent url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat 0 -80px;}* html .cd_title{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -659px transparent;}* html .sbTable .shadowTopLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px 0;}* html .sbTable .shadowTopRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -12px;}* html .sbTable .shadowLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  repeat-y 0 0;}* html .sbTable .shadowRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  repeat-y -12px 0;}* html .sbTable .shadowBotLeft{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -36px;}* html .sbTable .shadowBotRight{background: transparent url('../img/facelift/facelift-textbox-sprite.gif?42.27.0')  no-repeat -24px -24px;}* html .menulist li a{background: transparent url('../img/facelift/resultsIconSprite.gif?42.27.0')  no-repeat 0 0;}* html .tblNav .tblToggleBtn{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -40px transparent;}* html .tblNav .tblToggleBtn.tblToggleBtnPlus{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -20px transparent;}* html .firstDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -322px transparent;}* html .secondDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -342px transparent;}* html .scheduledDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -382px transparent;}* html .continuousDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -363px transparent;}* html .onlineDel{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -683px transparent;}* html .xmlLink.xmlLinkWithIcon{background : url('../img/facelift/facelift-icon-sprite.gif?42.27.0')  no-repeat scroll 0 -400px transparent;}* html .DJIIFilterList .pill,* html .DJIIFilterList .pill .filterText,* html .DJIIFilterList .pillNoMenu,* html .DJIIFilterList .pillNoMenu .filterText,* html .DJIIFilterList .filterConnection,* html .DJIIFilterList .filterConnection .connectionText,* html .pillOptionsList .pillOption,* html .pillOptionsList .pillOption span{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html #fdtHldContainer{background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x 0 0;}* html .cd_expand{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}* html .buttons .btn .prettyBtn{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html .buttons .btn .prettyBtn span{background-image : url('../img/facelift/facelift-main-nav-sprite.gif?42.27.0') ;}* html .nextItem,* html .previousItem{background-image : url('../img/facelift/facelift-icon-sprite.gif?42.27.0') ;}#qooverlay .buttons{margin-top:16px;}#qooverlay .overlayline{margin-bottom:5px;}#qocompanylist{height:70px;overflow:auto;position:relative;}.overlaycompanylistProgress{border:1px solid #CCC;}.NewsPages #contentWrapper #contentLeft{float:left;width:36%;}.NewsPages #contentWrapper #contentRight{float:left;margin-left:15px;width:59%;}.cssRemoveOverFlowIPAD{height:auto!important;overflow:hidden!important;}.NewsLetter{margin:0;}.WorkSpace{margin:0;}.NewsLetter #contentWrapper{padding:0;}.cssGroupFolder{background : url('../img/blueDott.JPG?42.27.0')  no-repeat scroll 0 0 transparent!important;height:10px;padding-left:15px;}.cssNoDisplay{display:none;}.snippet b{font-weight:bold;}.pagePadding{margin-left:10px;margin-right:10px;}#NLContainer td{padding:0;}#mbBody #selectAll,#mbBody #selectAll a{height:17px;width:15px;}#mbBody #selectAll,#mbBody #selectAll a{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -245px -130px transparent;}#mbBody #clearAll,#mbBody #clearAll a{height:17px;width:15px;}#mbBody #clearAll,#mbBody #clearAll a{background : url('../img/sprite_icons.gif?42.27.0')  no-repeat scroll -245px -150px transparent;}#mbBody .headlineHeader{padding-bottom:5px;background-color:#ccc;padding-left:5px;padding-right:5px;padding-top:5px;margin-bottom:10px;height:1%;}.showButllet{background : url('../img/arrowb.gif?42.27.0')  no-repeat 2px 4px transparent!important;zoom:1;}.overlaylist .lookupdyn{display:none;}a.sbIcon img{display:inline-block!important;vertical-align:baseline!important;}.overlaycontainer .mnuItmInc{color:#55B0EB!important;text-decoration:none!important;}.overlaycontainer .mnuItmExc{color:#55B0EB!important;text-decoration:line-through!important;}.overlaycontainer .addFiiCode{display:none!important;}.overlaycontainer a.sbIcon{width:0!important;padding-left:5px;}.overlaycontainer .availLbl{margin-left:25px;_margin-left:15px;}.overlaycontainer .availLbl img{_margin-bottom:5px;}#mdsLookupControl a:visited,#mdsLookupControl a:link,#mdsLookupControl a:hover{text-decoration:underline!important;}#chrtHCorpBond .WidgetContainer{background-color:#e5e5e5!important;}.WidgetBodyControls{position:relative;}.overlaylist .availSrchLbl{margin-left:25px!important;}.overlaylist .sbImg{margin-left:10px!important;}.NewsFiltersFilter{-moz-border-radius:5px;display:block;float:left;line-height:20px;margin-right:5px;padding-left:5px;margin-bottom:2px;background-position:0 -402px;background-image : url('../img/facelift/facelift-main-nav-sprite.png?42.27.0') ;}.NewsFiltersFilter .label{float:left;line-height:20px;white-space:nowrap;}.NewsFiltersFilter .icon-close{background-image : url('../img/icon_filter_close.png?42.27.0') ;background-position:center top;cursor:pointer;display:block;float:left;height:20px;width:20px;}.NewsFiltersFilter .icon-close:hover{background-position:center bottom;}.filterTextRemove{background-position:right -857px!important;}.DJIIFilterList .pill:hover .filterTextRemove,.DJIIFilterList .active .pill .filterTextRemove{background-position:right -892px!important;}.alphaHdr{background-color:#F0F0F0!important;cursor:default;}.alphaHdr a{padding-right:3px;}#dialogWindow .header .close{background-image:none!important;}body.framed #headlines{overflow:auto;overflow-x:hidden;}body.framed #headlineFrame{float:left;width:50%;}#returnToHeadlines{display:none;}body.articleView #returnToHeadlines{display:inline-block;margin:4px 0 0;vertical-align:middle;position:relative;}#returnToHeadlines a{padding:4px;}body.articleView #ppsview,body.articleView #viewSelected,body.articleView #headlineSort,body.articleView #dedupDropdown{display:none;}#headlineSort,#viewSelected{display:inline;}#pageFooter{clear:both;}.headline a:active{color:#007ec5;text-decoration:none;}.headline a:hover{color:#007ec5;text-decoration:underline;}.headline a:visited,.headline a:visited{color:#007ec5;text-decoration:none;}.headline a.moreLikeThis,.headline a.moreLikeThis:visited{color:blue;font-weight:normal;text-decoration:none;}#headlines a b,.headlines a b{color:#000;}.headline a.moreLikeThis:hover{color:blue;font-weight:normal;text-decoration:underline;}.searchPreview td{border-bottom:solid 1px #CCC;padding:3px 0 3px 8px;}.searchPreview .label{color:#666;}body.framed #bottomHeadlineNav,body.articleView #bottomHeadlineNav{display:none;}body.headlinesView #bottomHeadlineNav{display:block;}div.indexingHeader span.left,div.indexingHeader span.right{float:left;position:relative;}div.indexingHeader span.right{float:right;}#articleFrame a.moreLikeThis{color:#666;text-decoration:none;}#articleFrame a.moreLikeThis:hover{color:#000;text-decoration:underline;}.indexingHeader{background-color:#FC3;font-weight:bold;padding:7px;}.indexingPanel{background-color:#FF9;}.articleComment{background-color:#FFC;padding:3px;}a.carryOverRmv:hover{color:Red;font-size:14px;font-weight:600;line-height:13px;text-decoration:underline;}.folderList{width:175px;}.viewType{padding-top:5px;}body.articleView .viewType{display:none;}span.hot{border:solid 1px #CCC;}span.hot span{border-left:solid 10px #F00;color:#F00;}span.new{border:solid 1px #CCC;}span.new span{border-left:solid 10px #F69;color:#F69;}span.mustRead{border:solid 1px #CCC;}span.mustRead span{border-left:solid 10px #9C0;color:#9C0;}span.comment{border:solid 1px #CCC;}span.comment span{border-left:solid 10px #FC0;color:#FC0;}#newsstandTitle{float:left;padding-bottom:10px;}#returnLink{float:right;padding-bottom:10px;}span.hldScore{font-weight:bold;}.linkhide{float:right;margin-right:10px;cursor:pointer;padding-right:1px;}div.dymFreeText{padding-bottom:0;margin-bottom:0;margin-right:10px;display:inline-block;height:20px;vertical-align:middle;width:100%;}* html div.dymFreeText{height:20px;padding-top:4px;padding-bottom:0;margin-bottom:0;margin-right:10px;}div.recognitiondym,#appliedFilters{padding-top:5px!important;padding-bottom:0!important;margin-top:2px;}div.recognitiondym{background : url('../img/facelift/shadowRepeating.png?42.27.0')  repeat-x scroll 0 0 transparent;margin:5px 0;padding-left:5px;border:solid 1px #DBDBE7;display:block;}.freeText{padding-left:5px;}.dymTitle{display:block;}.dymInput{padding:1px;margin:0;}.dymCollapsiblePanel{padding-top:3px;}.dymCollapsiblePanelCollapsed{padding-top:3px;display:none;}.dedupHd{display:none;}#dedupHoverHint{background-color:#FFFFC6;border:1px solid #CCC;font-size:10px;padding:5px;position:absolute;visibility:hidden;width:285px;z-index:10000;}#dedupHiddenHH{display:none;}dedupHoverHintShim{position:absolute;}.dedupCount{color:#309;font-style:normal;}#analyzeChecked{background-color:#F63;background-repeat:repeat-x;color:#FFF;font-family:Arial,Helvetica,sans-serif;font-size:11px;height:16px;padding-bottom:1px;padding-left:4px;padding-right:4px;padding-top:1px;text-align:center;}#analyzeChecked A:active,#analyzeChecked A:visited,#analyzeChecked A:link,#analyzeChecked A:hover{color:#FFF;font-family:Arial,Helvetica,sans-serif;font-size:11px;text-align:center;text-decoration:none;}.hintImg{border:0;padding:0;vertical-align:middle;}#feedHH{display:none;}.hoverHint{background-color:#FFFFC6;border:1px solid #CCC;font-size:10px;padding:5px;position:absolute;visibility:hidden;z-index:10000;}body.articleView TABLE#contentColumns{table-layout:fixed;}.viewAs{display:none;}body.articleView #articleViewAs{display:inline-block;}body.articleView #returnToPreviousPage{display:inline-block;margin:4px 0 0;vertical-align:middle;position:relative;}body.articleView #returnToPreviousPage a{display:block;padding:4px;}.hlAuthorLink{font-weight:normal;}.headline .leadFields a{color:#63c;font:1em Verdana,Geneva,sans-serif;font-weight:normal;text-decoration:none;}.headline .leadFields a:hover{color:#63C;font-weight:normal;text-decoration:underline;}#atlnk{outline:none;}.headerTd{background:#ffd659;padding:2px;}div.tabcontent{background:#FFFFE3;}#navtab table tr #tabselected,#navtab table tr #tabselected td{background:#FFFFE3;}#navtab table tr td table{cursor:pointer;}#ssButtonContainer{background : url('../img/left_button.gif?42.27.0')  no-repeat left center;height:32px;padding-left:5px;cursor:pointer;display:inline-block;_width:1%;}#ssButtonSubContainer{background : url('../img/right_button.gif?42.27.0')  no-repeat right center;height:32px;padding-right:5px;display:inline-block;}#ssButtonContent{background : url('../img/bg_button.gif?42.27.0')  repeat-x center center;height:32px;text-align:left;padding-left:5px;padding-right:5px;display:inline-block;font-size:10px;}#ssButtonContent2{padding-top:2px;font-weight:bold;white-space:nowrap;}#ssButtonContent3{font-weight:bold;color:#76D6FF;white-space:nowrap;}.ssButtonContent4{font-weight:bold;color:#FD0606;white-space:nowrap;height:32px;text-align:center;vertical-align:middle;padding-top:8px;}#likeThese{display:none;}#likeTheseDiv{width:450px;}.likeTheseHeader{font-weight:bold;}.likeTheseInputWrapper{padding:10px 5px 5px 5px;margin-left:10px;}.likeTheseSaveNoThanksDiv{padding:10px 20px 20px 10px;text-align:right;}#likeTheseDiv div.floatRight{display:none;}#likeTheseDiv .popupHdr{background : url('../img/nlPopupTabBG.gif?42.27.0')  repeat-x scroll right bottom transparent;}#likeTheseBody{background-color:#FFF;}.arHeadline{margin-left:5px;direction:rtl;unicode-bidi:embed;}.arsnippet{direction:rtl;unicode-bidi:embed;}.arTextAlign{text-align:left;}.arArticle{text-align:right;}.ararticleParagraph{direction:rtl;unicode-bidi:embed;text-align:right;}.arLeadField{text-align:right;}.arArticle table{width:100%;}#headlineTabs.selectedTabAll #articleViewAs{display:none;}a, a:hover,.headline a,.headline a:hover,.headline a:active,.headline a:visited {text-decoration:none;color:#000;cursor:text;}#contentWrapper {border:none;background:none;}img,input, select,#menubarleft,#menubarright,#navcontainer ul,#breadtrail,#postProcessingNav,.content-header a,.industryReportHeader a {visibility:hidden;display:none;}#navcontainer {margin:40px 10px 0 10px;padding:0px 10px 0 10px;border-bottom:solid 1px #DEDEE9;}#navcontainer h1 {margin:0;padding:0;font-size:24px;font-weight:normal;}#navcontainer .djrlogo {visibility:visible;}#snapshotHeader {border:none;}#headlineFrame, #carryOver {padding-left:10px;}.article {page-break-after:always;}#lastArticle {page-break-after:auto;}html>body #lastArticle {page-break-after:avoid;}</style>

</head>
<body class=''><div id="navcontainer" class="fcpNavContainer">
<table cellpadding="0" cellspacing="0" border="0" width="100%">
<tr>
<td class="factivalogo"><h1>Factiva</h1></td>
<td class="djrlogo" align="right"><span>Dow Jones</span></td>
</tr>
</table>
</div>
<form name="PageBaseForm" method="post" action="/aa/default.aspx?pp=Save&amp;hc=Publication" id="PageBaseForm">
<div>
<input type="hidden" name="_XFORMSESSSTATE" id="_XFORMSESSSTATE" value="AB57MDp7MTU5Ons4OiJtYm0wLTAiLDA6MCwyOiJTIiwzOlsiMTQ2Il0sNDoiZW4iLDWABQJ1YWxidLwEDTE6MSwyOjAsMzoiMkNBTiJgBQZhbm5hLm1haEB8BARlcnRhLmNhaAcPIjE2Iiw2OnswOns0OiIwMDg2bAgNImNvZXhlLDAsMDtjb3RyboQBAA1lbnR3c2pwLDI7Y29jdXMsMCIsMToiZHRtb24sMCJ9cAEAFjgyMjIwNEY2ODAwMkE0MDA3MjEyNDY0MkJERDY4NUUwMjQwRTgwMHxqAHwwMQQAAy0xIn0sN5gRBzEyOiJBbGwiLDGdATFcCwsyNiwyOjF9LDg6MCwxMIUce3gAwR59jBADRjA4QzIwfAwPODAyNjAwMUJDfDAyMTAwMTEwKQMAMjEydQEzcAAFMDAxMDAzMDKgEgYifX0sNjowLDe0LwAHIn0sVToiL2FhL2RlZmF1bHQuYXNweCJ9fREAAKcBAAA=" />
<input type="hidden" name="_XFORMSTATE" id="_XFORMSTATE" value="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" />
<input type="hidden" name="__VIEWSTATE" id="
__VIEWSTATE" value="" />
</div>
<div id="contentWrapper"><div id="contentLeft"><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>Stockertown rallies behind mom's battle for tot's sight: Hali Heffelfinger wants gene therapy for her six-month-old daughter.</b>
</div><div class="author">By Marion Callahan, The Morning Call, Allentown, Pa.   </div><div>McClatchy-Tribune Regional News</div>
<div>1023 words</div><div>5 June 2008</div><div>The Morning Call (MCT)</div><div>KRTAA</div><div>English</div><div>Distributed by McClatchy - Tribune Information Services.   </div>
</p>
<p class="articleParagraph enarticleParagraph">Jun. 5--You'd never know from the smiles and high-pitched coos that trickle from 6-month-old Averi in the arms of her mother.</p>
<p class="articleParagraph enarticleParagraph">But her eyes give it away, the darting from one corner to the other, the distant gaze without a focus.</p>
<p class="articleParagraph enarticleParagraph">"At some point I just knew she wasn't seeing me," said Hali Heffelfinger. The 30-year-old single mom got the diagnosis she feared last month after a visit to an eye specialist in Hershey.</p>
<p class="articleParagraph enarticleParagraph">Heffelfinger, a waitress at Devery's Pub in Stockertown, struggled with the news. She shared Averi's diagnosis with her co-workers. Regular customers eventually caught on.</p>
<p class="articleParagraph enarticleParagraph">In Stockertown's mile-square community of only 750 residents, word spread quickly that Averi had been diagnosed with retinal degeneration and that surgical options were financially out of reach for the waitress. Sympathetic words and gestures followed. Next came offers to help, first from two regular customers who wanted to pay for Heffelfinger to seek a second opinion, then from neighboring businesses.</p>
<p class="articleParagraph enarticleParagraph">The impulse to do something for Averi and the friendly, red-haired waitress nicknamed "Cherrybomb" became contagious.</p>
<p class="articleParagraph enarticleParagraph">"It's emotionally overwhelming to know people would offer that kind of support," said Heffelfinger, who lives in Plainfield Township with her mother. "I can't even describe how I felt. I just started crying."</p>
<p class="articleParagraph enarticleParagraph">Pub owner Eileen Devery and customer Terry Kichline brainstormed about how to unite the community effort. The answer came from owners of the Saw Mill Golf Course across the street, who offered to reserve their course for a fundraiser.</p>
<p class="articleParagraph enarticleParagraph">On Sunday, more than 106 golfers and dozens of friends, family and community members gathered to take part in the Fight for Sight Charity Golf Tournament, which raised $8,500 for Averi's future medical bills.</p>
<p class="articleParagraph enarticleParagraph">Pub customer Jim Lynn made signs for the event and baked 40 pounds of ziti. Community shops and businesses posted fliers and donated gift certificates.</p>
<p class="articleParagraph enarticleParagraph">"This story is not about pity for a single mom facing a devastating situation," said Kichline, adding that strangers have stopped by the pub to drop off checks. "This is a story about a community coming together to care for their own."</p>
<p class="articleParagraph enarticleParagraph">Cradling Averi one recent day in the pub, Devery said Heffelfinger's personality brings warmth and cheer to the family pub.</p>
<p class="articleParagraph enarticleParagraph">"She's been with us for eight years, she's a good person and we love her," said Devery, watching as Heffelfinger, who was not working, wiped down nearby tables out of habit.</p>
<p class="articleParagraph enarticleParagraph">Looking back, Heffelfinger said, it's hard to imagine she took the job "on a whim."</p>
<p class="articleParagraph enarticleParagraph">"I had a full-time job but decided to apply to make some extra money," said Heffelfinger, who said the pub grew to become like a second home and her co-workers like a second family.</p>
<p class="articleParagraph enarticleParagraph">When Averi was born, Heffelfinger said Devery and co-workers dropped by the hospital with $200 to help her get through maternity leave.</p>
<p class="articleParagraph enarticleParagraph">Averi was born 7 pounds, 9 ounces in November. She had red hair, like her mother's, and loved to play with her feet. Heffelfinger would jiggle toys in front of Averi to spark a reaction, but nothing happened. Smiles came with sounds, especially when Heffelfinger sang "Itsy-Bitsy Spider" and "You Are My Sunshine." Belly laughs followed when the two danced in the living room. But their eyes never met.</p>
<p class="articleParagraph enarticleParagraph">"Her eyes would jump around and they never really followed me. Some of her toys would light up, but she never batted an eye," said Heffelfinger.</p>
<p class="articleParagraph enarticleParagraph">Heffelfinger's local doctor referred them to a pediatric eye specialist at Hershey Medical Center in Dauphin County. Though testing is still being done, Dr. Joel Weinstein suspects Averi has Leber congenital amaurosis, a genetic condition in which both parents must be carriers.</p>
<p class="articleParagraph enarticleParagraph">"As far as I can tell, she can see light and dark but not a lot else," said Weinstein, adding that Averi's constant rubbing of the eyes and sensitivity to light support that diagnosis.</p>
<p class="articleParagraph enarticleParagraph">Heffelfinger said the doctor explained it this way to her: "...Your eye is like a camera and the retina is like the film and, with Averi, the film is not processing."</p>
<p class="articleParagraph enarticleParagraph">"It meant she was blind and that her seeing potential will likely be shadows."</p>
<p class="articleParagraph enarticleParagraph">Heffelfinger's hope now rests on experimental gene therapy. The new procedure, which has helped a few people regain sight, involves injecting a virus containing the healthy gene into the retina of the eye.</p>
<p class="articleParagraph enarticleParagraph">Weinstein is awaiting results of a test that will reveal whether Averi is a viable candidate for this therapy. Such experimental procedures are not covered by Medicaid, Heffelfinger's insurance carrier.</p>
<p class="articleParagraph enarticleParagraph">The money from the golf tournament, she said, will open doors to medical options she wouldn't otherwise have.</p>
<p class="articleParagraph enarticleParagraph">"I know it seems sometimes that people don't care the way they used to, but here, it's not like that," she said. "This community is a blessing."</p>
<p class="articleParagraph enarticleParagraph">For now, Heffelfinger said she's preparing for an adventure, tapping into early intervention services to help her raise Averi and reading up on new breakthroughs in gene therapy.</p>
<p class="articleParagraph enarticleParagraph">"In this day and age with technology, I know sooner or later there will have to be something," Heffelfinger said. "Averi might be able to see things and be able to have a better life. It's hard knowing that my little girl won't be able to see the world as we see it."</p>
<p class="articleParagraph enarticleParagraph">Heffelfinger then looked down at the play mat in her living room, where Averi banged on the plastic keys of a toy piano with the heels of her feet.</p>
<p class="articleParagraph enarticleParagraph">"Right now, she doesn't know the difference. She's the happiest baby ever."</p>
<p class="articleParagraph enarticleParagraph">marion.callahan@mcall.com</p>
<p class="articleParagraph enarticleParagraph">610-559-2146</p>
<p class="articleParagraph enarticleParagraph">-----</p>
<p class="articleParagraph enarticleParagraph">To see more of The Morning Call, or to subscribe to the newspaper, go to http://www.mcall.com[http://www.mcall.com].</p>
<p class="articleParagraph enarticleParagraph">Copyright (c) 2008, The Morning Call, Allentown, Pa.</p>
<p>Document KRTAA00020080605e465000b8</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'> Experimental gene therapy improves sight for the blind</b>
</div><div class="author">Tom Avril         The Philadelphia Inquirer   </div><div>2816 words</div><div>4 May 2008</div><div>Charleston Gazette</div><div>CGAZ</div><div>P4A</div><div>English</div><div>(Copyright 2008)   </div>
</p>
<p class="articleParagraph enarticleParagraph">PHILADELPHIA - The young man on Albert Maguire's operating table had a big red mark stamped on the right side of his forehead.</p>
<p class="articleParagraph enarticleParagraph">The mark told the surgeon just where to insert his needle: straight into the patient's right eye.</p>
<p class="articleParagraph enarticleParagraph">Maguire didn't really need the reminder. He and his wife, molecular geneticist Jean Bennett, had been focusing on this moment for months - in truth, for decades.</p>
<p class="articleParagraph enarticleParagraph">The patient was blind. Maguire's hair-thin needle traveled through the "white" of his eye, all the way back to his badly scarred retina, where it would deliver billions of genetically modified viruses. Each virus carried a single gene: the recipe to produce a crucial enzyme that his eye was unable to make on its own.</p>
<p class="articleParagraph enarticleParagraph">Within weeks, beyond what anyone had predicted, the experiment worked. The young man and two other patients began to regain some vision.</p>
<p class="articleParagraph enarticleParagraph">The results, reported online this week by the New England Journal of Medicine, represent a dramatic advance in the field known as gene therapy, a field marked by sparkling - yet so far largely unfulfilled - promise.</p>
<p class="articleParagraph enarticleParagraph">Still legally blind</p>
<p class="articleParagraph enarticleParagraph">The three patients, treated in a joint effort by the University of Pennsylvania and Children's Hospital of Philadelphia, remain legally blind, but there are indications that the procedure might work even better in children, and the lessons one day could apply to other forms of inherited blindness.</p>
<p class="articleParagraph enarticleParagraph">"This Philadelphia trial is exceptionally exciting," said Savio Woo, a gene-therapy specialist at the Mount Sinai School of Medicine who was not involved with the study. "It's absolutely remarkable."</p>
<p class="articleParagraph enarticleParagraph">The Inquirer followed the trial over eight months under the agreement that it would not print an account until the research was published in an academic journal.</p>
<p class="articleParagraph enarticleParagraph">The official goal of the surgery was to make sure such an injection was safe; no one promised the young man, who had flown from Italy for the experimental treatment, that he would see any better.</p>
<p class="articleParagraph enarticleParagraph">Luck was on his side, though.</p>
<p class="articleParagraph enarticleParagraph">Bennett and Maguire set the date of the surgery for Thursday, Dec. 13.</p>
<p class="articleParagraph enarticleParagraph">To them, it was just another day on the calendar. To the Italian clinicians assisting in the operation, it was auspicious.</p>
<p class="articleParagraph enarticleParagraph">The 13th is the feast day of Santa Lucia, patron saint of the blind.</p>
<p class="articleParagraph enarticleParagraph">Jean Bennett and Albert Maguire first talked about the eye idea as they were finishing up Harvard medical school in the mid-1980s - she exploring the fledgling field of genetics, he learning to be a surgeon.</p>
<p class="articleParagraph enarticleParagraph">The two had hit it off in neuro-anatomy class. They were lab partners on the day they had to dissect a human brain.</p>
<p class="articleParagraph enarticleParagraph">After they cut the brain in half, Maguire took Bennett's hand and put it on top of the hypothalamus.</p>
<p class="articleParagraph enarticleParagraph">"I want to show you my favorite organ," he said, reminding her that it is sometimes called the "pleasure center."</p>
<p class="articleParagraph enarticleParagraph">Not missing a beat, she responded:</p>
<p class="articleParagraph enarticleParagraph">"That's my second-favorite organ."</p>
<p class="articleParagraph enarticleParagraph">They were married two years later.</p>
<p class="articleParagraph enarticleParagraph">'Fix gene, fix disease'</p>
<p class="articleParagraph enarticleParagraph">It was 1985. Still in school, Maguire was working in a lab that specialized in retinal degeneration, and he knew that many such diseases were the result of a single defective gene. With the practical, fix-it approach common to those in the surgical profession, Maguire wondered if matters could be addressed in the operating room.</p>
<p class="articleParagraph enarticleParagraph">"I thought: 'Simple problem: Fix gene, fix disease,'" he said.</p>
<p class="articleParagraph enarticleParagraph">Of all the body's organs, the eye is one of the most accessible. So he asked his wife, who already had a Ph.D. in biology: Was it possible to inject a corrective gene?</p>
<p class="articleParagraph enarticleParagraph">Sure, she said - in theory. Researchers had been talking for years about the goal of inserting genes into living tissue.</p>
<p class="articleParagraph enarticleParagraph">Except that no one had identified any of the genes that cause retinal disease.</p>
<p class="articleParagraph enarticleParagraph">"Had I actually known how difficult and complex the problem really was, I probably would have dismissed the idea immediately," he says now. "Jean has a more long-term view, and didn't tell me."</p>
<p class="articleParagraph enarticleParagraph">The two did a stint at Yale, where Bennett had grown up, the daughter of a famous physicist who co-invented the gas laser.</p>
<p class="articleParagraph enarticleParagraph">Later, Maguire interviewed for a fellowship with Robert Machemer, a pioneer in retinal surgery, and eagerly told him what he and his wife were trying to do. The response was not good.</p>
<p class="articleParagraph enarticleParagraph">"It'll never work," Machemer said.</p>
<p class="articleParagraph enarticleParagraph">Maguire, a Philadelphia native and Episcopal Academy graduate, didn't get the fellowship, but the rejection inspired the couple. They went to the University of Pennsylvania's prestigious Scheie Eye Institute in 1992.</p>
<p class="articleParagraph enarticleParagraph">The notion that eye problems could be inherited dates back to Aristotle, but the first gene for retinal degeneration was not discovered until 1989. Today, more than 400 eye-disease genes have been identified, aided by the Human Genome Project.</p>
<p class="articleParagraph enarticleParagraph">At Penn, Bennett studied the genetics of retinitis pigmentosa - a group of inherited diseases that gradually destroy sight.</p>
<p class="articleParagraph enarticleParagraph">In 1997, scientists at the National Eye Institute found a mutation that caused a rare subtype that strikes children, called Leber's congenital amaurosis (LCA). They began to try to induce these mutations in mice in order to figure out how to fix them.</p>
<p class="articleParagraph enarticleParagraph">Then, in 1998, Cornell University's Gregory Acland and Gustavo Aguirre - now at Penn - reported that the same mutation occurred naturally in a certain breed of dog, the Briard.</p>
<p class="articleParagraph enarticleParagraph">In 2000, Bennett and Maguire joined them in a pivotal experiment. They injected three blind dogs with a virus - one that had been modified to deliver the recipe for a missing enzyme in their eyes.</p>
<p class="articleParagraph enarticleParagraph">Within weeks, the dogs' vision improved more than anyone had hoped. They could see so well they could navigate a maze.</p>
<p class="articleParagraph enarticleParagraph">By 2006, Maguire had performed the surgery on 55 blind dogs, restoring vision in more than 90 percent of them.</p>
<p class="articleParagraph enarticleParagraph">Time to try it on people</p>
<p class="articleParagraph enarticleParagraph">LCA is a rare disease, afflicting perhaps 3,000 people in the United States. If Bennett and Maguire could get their gene therapy to work for that illness, the lessons might apply to other forms of retinitis pigmentosa - which strikes 100,000 people in the United States.</p>
<p class="articleParagraph enarticleParagraph">It was time to try it on people.</p>
<p class="articleParagraph enarticleParagraph">Giuseppe Ferraro noticed, when his firstborn son was 5 months old, that the baby didn't seem bothered by bright lights. In fact, he looked straight at them.</p>
<p class="articleParagraph enarticleParagraph">Eventually, Ferraro learned that his son had LCA.</p>
<p class="articleParagraph enarticleParagraph">His vision had been impaired since birth, and it would become steadily worse.</p>
<p class="articleParagraph enarticleParagraph">There was no cure.</p>
<p class="articleParagraph enarticleParagraph">Four years later, the Ferraros had twins. Sadly, Tommaso and Josalinda were born with the same mutation.</p>
<p class="articleParagraph enarticleParagraph">Tommaso grew up and got a job as a dispatcher for the forest service, where a government-appointed guide helps him get around. Josalinda got married and began to raise two children. Each could see a little bit out of one eye, especially in bright sunlight, but under normal interior lighting, their vision was just about zero.</p>
<p class="articleParagraph enarticleParagraph">Through doctors in Naples, they heard that scientists in Philadelphia were working on an experiment that might help them.</p>
<p class="articleParagraph enarticleParagraph">Tommaso and Josalinda were 26. The trial was limited to those 27 and under; any older, and the retina likely would be beyond rescue.</p>
<p class="articleParagraph enarticleParagraph">Tommaso was a little hesitant when he heard that a needle would be inserted into his right eye. Also, the doctors warned him, his eye could become inflamed. The corrective genes, borne by the viruses, might not take hold. His brain - starved of visual information for decades - might have trouble making sense of the new signals coming from his rejuvenated eye.</p>
<p class="articleParagraph enarticleParagraph">Yet the doctors seemed confident not only that the procedure was safe - but that he might even regain some vision.</p>
<p class="articleParagraph enarticleParagraph">He and his twin sister agreed to try it. They booked flights to Philadelphia.</p>
<p class="articleParagraph enarticleParagraph">One crucial protein</p>
<p class="articleParagraph enarticleParagraph">In people with normal vision, a crucial protein is made by the retinal pigment epithelium, a layer of cells beneath the retina. The protein, an enzyme called RPE65, is used to metabolize vitamin A. The metabolized vitamin, in turn, allows the nearby "rod" cells to make a pigment that absorbs light, so it can be converted into an electrochemical message to the brain.</p>
<p class="articleParagraph enarticleParagraph">People with an RPE65 mutation develop LCA. Their eyes make flawed versions of the protein, if any at all.</p>
<p class="articleParagraph enarticleParagraph">Not only is their vision impaired to begin with, but over the years, their cells accumulate toxic levels of a vitamin A derivative that normally is broken down by RPE65. Their retinas become badly scarred.</p>
<p class="articleParagraph enarticleParagraph">To do gene therapy, Bennett's team took the virus and gutted it. They replaced its two genes with a single human gene - one with the blueprint for a healthy version of RPE65. All that remained of the original virus DNA was a pair of genetic bookends, one on each end of the DNA molecule.</p>
<p class="articleParagraph enarticleParagraph">Fraser Wright, director of the Children's Hospital lab that made the viral "vector" - the carrier - worked with Jeannette Bennicelli and others to fine-tune it. They added various bits of customized genetic material, including a "promoter" to enhance production of the needed enzyme, and another sequence to make the virus even better at penetrating the patients' eye cells.</p>
<p class="articleParagraph enarticleParagraph">The lab grew and purified billions of the viruses. It cultivated them inside cells derived from human kidneys, using a growth medium and other materials that had been subjected to rigorous tests to ensure purity. That process took a whole year.</p>
<p class="articleParagraph enarticleParagraph">Wright's lab performed dozens of FDA-mandated tests on the virus itself to ensure it would be safe for people - that there was no contamination by other viruses or bacteria, for instance.</p>
<p class="articleParagraph enarticleParagraph">The lab made hundreds of vials and stored them in a freezer.</p>
<p class="articleParagraph enarticleParagraph">Nine patients would receive the injection, each time in their worse eye - in case there were complications. The first three were the twins, Tommaso and Josalinda, and another Italian woman named Manuela Migliorati. (The disease is no more common in Italy than anywhere else, but researchers there have made an effort to identify those with mutations.)</p>
<p class="articleParagraph enarticleParagraph">If all went well, the viruses would latch onto and enter the sub-retinal cells, then travel all the way to the cells' nuclei. There, each virus would ordinarily release its own DNA, but in the patients, the lab-modified virus instead would release its cargo of the new RPE65 gene.</p>
<p class="articleParagraph enarticleParagraph">15 billion viruses each</p>
<p class="articleParagraph enarticleParagraph">Because retinal cells do not divide, the impact of the corrective gene would not be watered down over time. It should be permanent.</p>
<p class="articleParagraph enarticleParagraph">The first three patients were to get 15 billion viruses each. If everything went OK, the next three would get three times that many. The third group would get 150 billion - 10 times the first dose.</p>
<p class="articleParagraph enarticleParagraph">Al Maguire decided two days in advance just where he would insert the needle into Tommaso's right eye.</p>
<p class="articleParagraph enarticleParagraph">In October, with Tommaso's sister Josalinda, he'd injected the virus away from the center of the retina, in case it somehow impaired what little vision she had.</p>
<p class="articleParagraph enarticleParagraph">There were no complications with Josalinda, so Tommaso would get his injection closer to the center.</p>
<p class="articleParagraph enarticleParagraph">Because Tommaso was young, the clear substance inside his eye - called the vitreous - was still fairly firm and jelly-like. The needle, a flexible instrument called a cannula, could not be inserted all the way back to the retina.</p>
<p class="articleParagraph enarticleParagraph">So first, the surgical team removed the jelly and simultaneously replaced it with a saline solution - a procedure called a vitrectomy.</p>
<p class="articleParagraph enarticleParagraph">The surgeons cut three tiny holes in the surface of the eye: one for a vitrector, an instrument to snip and gently suck out the jelly; one for an infusion port to pump in the saline solution; and one for a "light pipe" to illuminate the back of the eye.</p>
<p class="articleParagraph enarticleParagraph">It was time for the injection.</p>
<p class="articleParagraph enarticleParagraph">"Go, go, go!"</p>
<p class="articleParagraph enarticleParagraph">Maguire held the light pipe in his left hand. He carefully inserted the cannula with his right.</p>
<p class="articleParagraph enarticleParagraph">The flexible needle went through the sclera - the "white" of the eye - then through the saline fluid, until Maguire felt it come to rest at the back of the eye, gently, against the retina.</p>
<p class="articleParagraph enarticleParagraph">The needle was connected to a syringe in the hands of Penn ophthalmologist Eric Pierce, who stood ready to push the button that would release the precious genetic material.</p>
<p class="articleParagraph enarticleParagraph">"Push, push," Maguire told Pierce.</p>
<p class="articleParagraph enarticleParagraph">Looking through his microscope, Maguire saw a "bleb" - a small spot where the entering fluid was causing Tommaso's retina to rise. That meant he had gotten the needle in the right place.</p>
<p class="articleParagraph enarticleParagraph">"Go, go, go!" he urged Pierce, so he would release the rest of the virus-bearing fluid.</p>
<p class="articleParagraph enarticleParagraph">After years of preparation, the actual injection had taken just a few moments.</p>
<p class="articleParagraph enarticleParagraph">At 3:45 p.m., Maguire emerged in his hospital scrubs to give the news to the patient's father; an Italian doctor translated.</p>
<p class="articleParagraph enarticleParagraph">"He's doing very well," Maguire said. "He's waking up from the anesthesia. The injection went perfectly."</p>
<p class="articleParagraph enarticleParagraph">Maguire's focus is surgery, but he has the utmost respect for his wife's work as a scientist and her role outside the lab. She gamely attends black-tie fundraisers, patiently explaining her work to potential donors. Ever cheerful, she acts like a big sister to her three patients.</p>
<p class="articleParagraph enarticleParagraph">She played tour guide while they recovered from surgery, taking each to <span class="companylink">FAO Schwarz</span> and Times Square in New York, and to the Franklin Institute in Philadelphia, where they rode the flight simulator.</p>
<p class="articleParagraph enarticleParagraph">'She can see the photos!'</p>
<p class="articleParagraph enarticleParagraph">The third patient, Manuela, liked the simulator best. A 19-year-old university student, she was a bit of a daredevil and a downhill skier, with the best vision of the three.</p>
<p class="articleParagraph enarticleParagraph">Still, she was legally blind. When Bennett gave her some 8-by-10 photos of their sight-seeing trip to take back to Italy, Manuela couldn't make out the details.</p>
<p class="articleParagraph enarticleParagraph">Then, just two weeks after her surgery, she sent Jean Bennett an e-mail.</p>
<p class="articleParagraph enarticleParagraph">Manuela had looked at the photos again. To her delight, she wrote, she started to make out what was in them: herself, in the giant heart at the Franklin Institute, walking through Times Square, touching large stuffed animals at FAO Schwartz.</p>
<p class="articleParagraph enarticleParagraph">Bennett was elated. She grabbed the phone and started to call other members of the team. "Guess what? Manuela e-mailed me! She can see the photos!"</p>
<p class="articleParagraph enarticleParagraph">Tommaso and Josalinda also had reported some improvement in their vision, just weeks after their surgeries. They did not notice much difference in broad daylight, but they could see more indoors and at night. They were better at distinguishing lights and darks. At work, Tommaso relied less on his government-appointed guide and more on his cane. He felt confident pushing his baby son in a stroller.</p>
<p class="articleParagraph enarticleParagraph">Bennett knew there had been a chance that the patients' vision could improve, but these first three were older, their eyes severely damaged, and they'd received a weaker dose of the vision virus.</p>
<p class="articleParagraph enarticleParagraph">She wanted to jump up on a table and shout. Still, as a scientist, she was cautious.</p>
<p class="articleParagraph enarticleParagraph">It was one thing for the patients to think they could see better, but the team needed hard data.</p>
<p class="articleParagraph enarticleParagraph">In March, Bennett flew her three Italian patients back to Philadelphia for tests.</p>
<p class="articleParagraph enarticleParagraph">With Bennett at her side, Josalinda peered into the twin eyepieces of the pupillometer, a device that repeatedly flashed light into her eyes.</p>
<p class="articleParagraph enarticleParagraph">Bennett needed to measure how much her pupils would constrict. Before the surgery, they barely responded.</p>
<p class="articleParagraph enarticleParagraph">For each round of testing, Josalinda kept her eyes closed until Bennett gave her the go-ahead, in a mixture of Italian and English.</p>
<p class="articleParagraph enarticleParagraph">"Uno, due, tre ... Open!" Bennett called out each time.</p>
<p class="articleParagraph enarticleParagraph">Then finally: "Bravo, bravo! You did a wonderful job."</p>
<p class="articleParagraph enarticleParagraph">Bennett would need to scrutinize the data, but the machine seemed to confirm what Josalinda and the other two patients had told her: Their vision had improved. Their eyes were apparently making the enzyme they needed for sight.</p>
<p class="articleParagraph enarticleParagraph">Later analysis would show that the injected eyes of all three patients became roughly three times as sensitive to light.</p>
<p class="articleParagraph enarticleParagraph">Furthermore, all three were better able to read eye charts - although they did so slowly, haltingly, sitting less than two feet away from letters a couple of inches tall.</p>
<p class="articleParagraph enarticleParagraph">Before the surgery, Tommaso's right eye could barely perceive someone waving a hand right in front of him. His eye was so bad it was hard to quantify, but compared to 20/20 vision, his right eye was at 20 over several thousand. After treatment, the eye improved to 20 over 710.</p>
<p class="articleParagraph enarticleParagraph">It had been 23 years since Bennett and her husband had first discussed the idea. Now, it had happened.</p>
<p class="articleParagraph enarticleParagraph">"To go from zero to anything, it's just ..." She shrugged, unable to finish her sentence.</p>
<p>Document CGAZ000020080506e45400042</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>Gene therapy restores some vision for blind</b>
</div><div class="author">STEPHANIE NANO, THE ASSOCIATED PRESS   </div><div>979 words</div><div>28 April 2008</div><div>The Record</div><div>REC</div><div>All Editions</div><div>A01</div><div>English</div><div> 2008 North Jersey Media Group Inc. Provided by ProQuest Information and Learning. All rights reserved.
   </div>
</p>
<p class="articleParagraph enarticleParagraph">NEW YORK Scientists for the first time have used gene therapy to dramatically improve sight in people with a rare form of blindness, a development experts called a major advance for the experimental technique.</p>
<p class="articleParagraph enarticleParagraph">Some vision was restored in four of the six young people who got the treatment, teams of researchers in the United States and Britain reported Sunday. Two of the volunteers who could only see hand motions were able to read a few lines of an eye chart within weeks.</p>
<p class="articleParagraph enarticleParagraph">"It's a phenomenal breakthrough," said Stephen Rose, chief research officer of the Foundation Fighting Blindness, which helped pay for one study done at Children's Hospital of Philadelphia.</p>
<p class="articleParagraph enarticleParagraph">If successful in larger numbers, experts said, the technique has the potential to reverse blindness from other kinds of inherited eye diseases.</p>
<p class="articleParagraph enarticleParagraph">"I think this is incredibly exciting," said Dr. Jean Bennett, a professor of ophthalmology at the University of Pennsylvania and a leader of the Philadelphia study. "It's the beginning of a whole new phase of studies."</p>
<p class="articleParagraph enarticleParagraph">The research was published online Sunday by the New England Journal of Medicine in conjunction with presentations at a medical meeting in Florida.</p>
<p class="articleParagraph enarticleParagraph">The two teams of scientists, working separately, each tested gene replacement therapy in three patients with a form of a rare hereditary eye disease called Leber's congenital amaurosis. There's no treatment for the disease, which appears early in infancy and causes severe vision loss, especially at night.</p>
<p class="articleParagraph enarticleParagraph">An estimated 2,000 Americans have the form of the disease they targeted, Bennett said.</p>
<p class="articleParagraph enarticleParagraph">Gene therapy replacing faulty genes with a normal version has been studied in humans for more than 15 years with limited success. The field suffered a setback with the 1999 death of Jesse Gelsinger, 18, in an experiment for a liver disorder at Penn. And some children treated for an immune disorder called the "bubble-boy disease" later developed leukemia.</p>
<p class="articleParagraph enarticleParagraph">The early results of the eye experiments should give the field a boost, some experts said.</p>
<p class="articleParagraph enarticleParagraph">"I think it's really a big shot in the arm for gene therapy and for medicine in general," said Dr. Ronald Crystal, head of genetic medicine at Weill Cornell Medical College in New York.</p>
<p class="articleParagraph enarticleParagraph">Each of the study participants had mutations in a gene that makes a protein needed by the retina, which senses light and sends images to the brain. Those without the gene gradually lose sight until they are blind in early adulthood.</p>
<p class="articleParagraph enarticleParagraph">The retina itself stays in relatively good shape for a while, making it a good candidate for gene therapy, said Robin Ali, a professor at University College London, who led the British team. He likened the defective gene to a missing spark plug in a car engine.</p>
<p class="articleParagraph enarticleParagraph">"The whole engine can be absolutely fine, but if it doesn't have a spark plug, the car's not going to work," Ali said.</p>
<p class="articleParagraph enarticleParagraph">One eye treated</p>
<p class="articleParagraph enarticleParagraph">For the experiment, the scientists injected millions of copies of a working gene beneath the retina in the back of the eye. Only one eye was treated the worse one in case anything went wrong; the untreated eye was used for comparison. After the treatment, participants' eyesight and light sensitivity were measured periodically; mobility was tested in a maze or an obstacle course.</p>
<p class="articleParagraph enarticleParagraph">All three of those treated in Philadelphia showed significant improvement in their vision, the researchers said. The volunteers two women, 19 and 26, and a man, 26 were from Italy, where they had been screened by researchers there. The longest follow-up was six months.</p>
<p class="articleParagraph enarticleParagraph">Besides reading lines on an eye chart, they could see better in dim light, Bennett said.</p>
<p class="articleParagraph enarticleParagraph">"We were not expecting to restore their vision to 20/20," she said.</p>
<p class="articleParagraph enarticleParagraph">In the British group, the treatment worked in 18-year-old Steven Howarth, whose disease was less advanced than the other two a girl, 17; and a man, 23, who was followed for a year.</p>
<p class="articleParagraph enarticleParagraph">Howarth said he used to rush home from school because he was worried about getting around in the dark, according to remarks issued by the university.</p>
<p class="articleParagraph enarticleParagraph">"Now, my sight when it's getting dark or it's badly lit is definitely better. It's a small change but it makes a big difference to me," Howarth said.</p>
<p class="articleParagraph enarticleParagraph">After the injection last July, Howarth said, his eye felt like sandpaper. It was better after a week, and his eyesight gradually improved. He was able to negotiate a dimly lit maze in 14 seconds without bumping into any obstacles; before, it took him 77 seconds with eight errors.</p>
<p class="articleParagraph enarticleParagraph">There were no serious side effects reported in either group. One of the patients in Philadelphia developed a hole in his retina which didn't affect his eyesight. The researchers think the hole was related to the surgery and not the injected gene.</p>
<p class="articleParagraph enarticleParagraph">The researchers said there was no evidence that the altered virus used to ferry the gene into the retina's cells had traveled outside the eye to other areas of the body.</p>
<p class="articleParagraph enarticleParagraph">Each of the groups has treated a fourth patient, including a preteen in England. The researchers hope to see better results with higher doses and in younger patients with less eye damage.</p>
<p class="articleParagraph enarticleParagraph">The National Eye Institute is funding a third similar study at the University of Florida.</p>
<p class="articleParagraph enarticleParagraph">The research in Philadelphia and London was paid for by a variety of government agencies and private foundations. An employee of <span class="companylink">Targeted Genetics Corp.</span>, which made the altered virus used in London, is a co-author of the report from that location.</p>
<p class="articleParagraph enarticleParagraph">Four of the Philadelphia researchers, including Bennett, have either applied for or already have patents related to gene therapy. Ali and another British researcher also have applied for a patent for the procedure.</p>
<p class="articleParagraph enarticleParagraph">***</p>
<p>Caption: GRAPHIC - AP - GENE THERAPY BREAKTHROUGH   </p>
<p>Document REC0000020080512e44s00043</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>Gene therapy gives hope to blind / Vision improved and sensitivity to light increased in new treatment</b>
</div><div class="author">THOMAS H. MAUGH II   </div><div>Los Angeles Times</div>
<div>791 words</div><div>28 April 2008</div><div>Houston Chronicle</div><div>HOU</div><div>3 STAR R.O. ; 0</div><div>3</div><div>English</div><div> 2008 Houston Chronicle.  Provided by ProQuest Information and Learning.  All Rights Reserved.
   </div>
</p>
<p class="articleParagraph enarticleParagraph">For the first time, researchers have used gene therapy to increase light sensitivity and improve vision in patients who were virtually blind, a finding that offers new hope to hundreds of thousands of patients with inherited forms of vision impairment.</p>
<p class="articleParagraph enarticleParagraph">Although the patients studied have an extremely rare form of blindness called Leber's congenital amaurosis, researchers believe the approach ultimately could be used for a much broader spectrum of disorders, including retinitis pigmentosa and macular degeneration.</p>
<p class="articleParagraph enarticleParagraph">The treatment, so far meant only to prove the safety of the technique, produced "real clinical benefit" and "made a real difference in patients' lives," said geneticist Robin R. Ali of University College London, the senior author of one of two reports presented Sunday at a Fort Lauderdale, Fla., meeting of the Association for Research in Vision and Ophthalmology.</p>
<p class="articleParagraph enarticleParagraph">Success after trying times</p>
<p class="articleParagraph enarticleParagraph">The reports were published online Sunday by the New England Journal of Medicine.</p>
<p class="articleParagraph enarticleParagraph">"The fact that they had patients who could now read lines on an eye chart ... and one who could run an obstacle course - this is a really great advance," said geneticist Stephen Rose, chief research officer of the Foundation Fighting Blindness, who was not involved in the research.</p>
<p class="articleParagraph enarticleParagraph">"This has changed the landscape of hope for patients," he said.</p>
<p class="articleParagraph enarticleParagraph">Added Dr. Morton F. Goldberg, an ophthalmologist at John Hopkins University's Wilmer Eye Institute, "In the field of retinal dystrophies, this is, I believe, the most important therapeutic discovery" in four decades. "It's a landmark."</p>
<p class="articleParagraph enarticleParagraph">The results are particularly important because gene therapy, in which a good gene is substituted for a naturally occurring defective one, has been "a snake-bitten field," with at least two subjects in other experiments dying and a handful of others developing cancer, said Dr. Albert M. Maguire of the University of Pennsylvania School of Medicine, lead author of the second report.</p>
<p class="articleParagraph enarticleParagraph">"We have been working for years, and it has really been rough," Maguire said. "Here we finally have something in a curable disease that really seems to be working."</p>
<p class="articleParagraph enarticleParagraph">Leber's congenital amaurosis affects about 3,000 people in the United States and perhaps one in every 50,000 worldwide. Children with the disorder are born with severely impaired vision that deteriorates over the course of their lives until they are totally blind in childhood or adolescence.</p>
<p class="articleParagraph enarticleParagraph">There is no treatment for it.</p>
<p class="articleParagraph enarticleParagraph">Other treatments possible</p>
<p class="articleParagraph enarticleParagraph">What makes Leber's a good candidate for gene therapy is that most of the visual apparatus, including the retina, is intact - at least at birth. Typically, the defective gene that produces it is one of several in a biochemical pathway that produces chemicals necessary for the eye to generate an electrical signal for transmission to the brain.</p>
<p class="articleParagraph enarticleParagraph">If that gene could be replaced before the visual apparatus deteriorates from lack of use, then vision could be restored, Maguire said.</p>
<p class="articleParagraph enarticleParagraph">That same basic strategy could be used to treat a variety of congenital retinal disorders. "With an aging population, one of the most serious problems that hinders old people is the loss of sight," said Dr. Katherine A. High of Children's Hospital of Philadelphia and a co-author of one of the studies.</p>
<p class="articleParagraph enarticleParagraph">Response to light improved</p>
<p class="articleParagraph enarticleParagraph">Retinitis pigmentosa - the broad family of disorders that includes Leber's - affects an estimated 100,000 Americans. Macular degeneration affects 1.25 million Americans now, and the number is expected to grow to 3 million by 2020 as the population continues to age.</p>
<p class="articleParagraph enarticleParagraph">Those conditions are caused by other defective genes, but the treatment principle would be the same.</p>
<p class="articleParagraph enarticleParagraph">The Pennsylvania group treated three patients, one age 19 and two age 26, recruited by Dr. Alberto Auricchio of the University of Naples Federico II in Italy.</p>
<p class="articleParagraph enarticleParagraph">Beginning two weeks after treatment, all three patients reported improved vision, Maguire said.</p>
<p class="articleParagraph enarticleParagraph">By measuring pupillary response to light - the only objective measure of vision the researchers were able to employ - they found light sensitivity had improved about threefold. The treatment also reduced nystagmus, an uncontrollable roaming of the eye often seen in blind people.</p>
<p class="articleParagraph enarticleParagraph">Patients also performed better on more subjective tests. One patient's vision on an eye chart, for example, improved from 20/640 to 20/290, about 3 1/2 lines of improvement, according to Dr. Jean Bennett, lead author of the study. The Food and Drug Administration requires three lines of improvement to consider a treatment efficacious.</p>
<p>Photo: LOOKING INTO IT: Dr. Albert Maguire and Dr. Jean Bennett at
the University of Pennsylvania are part of two teams of scientists
studying Leber's congenital amaurosis, an eye disease that causes
blindness.   </p>
<p>Document HOU0000020080429e44s00066</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>HEALTH & SCIENCE / A 'landmark' treatment</b>
</div><div>STAFF</div>
<div>31 words</div><div>28 April 2008</div><div>Houston Chronicle</div><div>HOU</div><div>3 STAR R.O. ; 0</div><div>1</div><div>English</div><div> 2008 Houston Chronicle.  Provided by ProQuest Information and Learning.  All Rights Reserved.
   </div>
</p>
<p class="articleParagraph enarticleParagraph">Researchers have uncovered new hope, in the form of gene therapy, for those with inherited types of vision impairment.</p>
<p class="articleParagraph enarticleParagraph">STORY ON PAGE A3</p>
<p>Document HOU0000020080429e44s0005y</p></div><br/><span></span><div  class="article enArticle"><p>
<div>NEWS</div>
<div id="hd" ><b class='enHeadline'>Gene therapy takes a step forward ; Hereditary blindness is helped in small study</b>
</div><div class="author">Liz Szabo   </div><div>477 words</div><div>28 April 2008</div><div>USA Today</div><div>USAT</div><div>FINAL</div><div>A.1</div><div>English</div><div> 2008 USA Today.  Provided by ProQuest Information and Learning.   All Rights Reserved.
   </div>
</p>
<p class="articleParagraph enarticleParagraph">For the first time, doctors have used gene therapy to restore vision in patients with a rare and usually incurable form of blindness, researchers announced Sunday.</p>
<p class="articleParagraph enarticleParagraph">Experts say the results are a welcome success in gene therapy, a promising idea that has had several major setbacks during the past 15 years.</p>
<p class="articleParagraph enarticleParagraph">"It's a breakthrough," says Ronald Crystal, chairman of the department of genetic medicine at New York's Weill Medical College of Cornell University. "It really helps to validate that gene therapy can work and is going to be important."</p>
<p class="articleParagraph enarticleParagraph">None of the six patients treated regained normal vision, but four have much better eyesight than before, according to two studies published online by The New England Journal of Medicine.</p>
<p class="articleParagraph enarticleParagraph">The patients had a rare inherited disorder called Leber's congenital amaurosis, which begins eroding eyesight at birth and leaves them blind by their mid-20s.</p>
<p class="articleParagraph enarticleParagraph">Though cataract surgery and medication can restore sight in patients with other eye ailments, doctors have never before been able to restore vision to patients with this kind of hereditary degenerative disease, says Albert Maguire, an associate professor at the University of Pennsylvania School of Medicine and co-author of one of the studies.</p>
<p class="articleParagraph enarticleParagraph">Leber's congenital amaurosis afflicts 2,000 to 10,000 people in the USA, says Maguire's co-author Jean Bennett, a professor at the University of Pennsylvania. There is no effective treatment. She hopes gene therapy may work for patients with more common kinds of blindness.</p>
<p class="articleParagraph enarticleParagraph">Two patients in her study began the trial barely able to see hand movements. After treatment, they became three times as sensitive to light and could read lines on an eye chart, according to an international team led by doctors at the Children's Hospital of Philadelphia and the University of Pennsylvania.</p>
<p class="articleParagraph enarticleParagraph">Stanford University researcher Mark Kay, former president of the American Society of Gene Therapy, says the studies suggest gene therapy may be most successful in patients in early stages of the disease, while they still have some vision.</p>
<p class="articleParagraph enarticleParagraph">In gene therapy, doctors aim to replace defective genes with normal ones, using harmless viruses as delivery vehicles, Crystal says.</p>
<p class="articleParagraph enarticleParagraph">Crystal says gene therapy may work particularly well with eye disorders because the immune system, which can reject the virus carrying the genes, isn't as active in the eye. And because it's easy to test vision, doctors know quickly whether the therapy works.</p>
<p class="articleParagraph enarticleParagraph">Despite high hopes for gene therapy, scientists have struggled to realize its potential.</p>
<p class="articleParagraph enarticleParagraph">For example, doctors have treated 20 to 30 children who suffer from a rare and severe immune disorder. Though most of the children are healthy, several developed leukemia. And in 1999, a teenager named Jesse Gelsinger died after gene therapy at the University of Pennsylvania.</p>
<p>Document USAT000020080428e44s0000q</p></div><br/><span></span><div  class="article enArticle"><p>
<div>A Section</div>
<div id="hd" ><b class='enHeadline'>Altered Viruses Reversed Progressive Blindness, Studies Say</b>
</div><div class="author">Rick Weiss   </div><div>Washington Post Staff Writer</div>
<div>1076 words</div><div>28 April 2008</div><div>The Washington Post</div><div>WP</div><div>FINAL</div><div>A05</div><div>English</div><div>Copyright 2008, The Washington Post Co. All Rights Reserved   </div>
</p>
<p class="articleParagraph enarticleParagraph">Three young adults barely able to see because of a congenital and progressive form of blindness have regained modest amounts of vision after getting genetically engineered viruses injected into their eyes, the leaders of two independent studies reported yesterday.</p>
<p class="articleParagraph enarticleParagraph">The results were something short of miraculous. Three other patients showed no increase in visual acuity, and the three who improved are still legally blind.</p>
<p class="articleParagraph enarticleParagraph">But to get any improvement at all during such an early phase of the research suggests that the approach has promise for people with gene-based forms of blindness, researchers said. The work could also provide a boost for the field of gene therapy, which for 15 years has tried and mostly failed to treat diseases by giving people new genes -- and in a few high-profile cases has sickened or even killed them.</p>
<p class="articleParagraph enarticleParagraph">"We're learning things as we go along," said Jean Bennett of the University of Pennsylvania, who with Albert M. Maguire led one of the two studies. "We were not really going for a cure. But we do view it as a success in that their vision has improved. I'd call it a dramatic response."</p>
<p class="articleParagraph enarticleParagraph">Others took a more conservative view, noting that some of the key measures of improvement were subjective and could not be conclusively linked to the therapy. In an editorial to appear in the New England Journal of Medicine along with the study results, Joan W. Miller of the Massachusetts Eye and Ear Infirmary called the results "suggestive of efficacy."</p>
<p class="articleParagraph enarticleParagraph">Still, videos of some of the experimental subjects trying to navigate through a dimly lit obstacle course show notable improvement in the weeks and months after the injections. Scientists said they are hopeful that the treatment will prove even more beneficial in younger patients, whose retinas have only begun to degenerate.</p>
<p class="articleParagraph enarticleParagraph">"If we can get any benefits in people with such advanced disease, then when we start to treat children, and when we treat a greater part of the retina and give a higher dose, the expectation is we can get even better results," said Robin R. Ali of University College London, who led the other study.</p>
<p class="articleParagraph enarticleParagraph">Both teams are moving ahead with tests in younger patients and at higher doses.</p>
<p class="articleParagraph enarticleParagraph">The experiments involve patients with Leber's congenital amaurosis, a rare disease caused by a defect in a single gene that is crucial to the retina's ability to convert light into signals to the brain. Affected children have impaired vision from birth and are typically blind by age 30.</p>
<p class="articleParagraph enarticleParagraph">The British and Pennsylvania teams took somewhat different approaches. Each involved what are known as adeno-associated viruses, popular among gene-therapy researchers because of their ability to deliver new genes to cells.</p>
<p class="articleParagraph enarticleParagraph">In this case, the teams used genetic engineering techniques to load the viruses with healthy versions of the rpe65 gene, the gene that is faulty in people with Leber's. Then they injected tens of billions of the viruses into the tiny space behind the retina.</p>
<p class="articleParagraph enarticleParagraph">They treated just one eye of each patient, in part so as not to put both eyes at risk of side effects but also to allow for comparisons of visual acuity after the treatment.</p>
<p class="articleParagraph enarticleParagraph">The Pennsylvania team, whose patients were ages 19 to 26, reported the more impressive results. All three scored better on visual acuity tests, showing improvements equivalent to being able to read three lines lower on a standard eye chart, after initially not being able to make out the very largest letter. The treated eyes of all three patients also became about three times more responsive to light as measured by how much the pupils contracted.</p>
<p class="articleParagraph enarticleParagraph">One patient suffered retinal damage, apparently as a side effect, though team members said they think they know how to avoid that in the future.</p>
<p class="articleParagraph enarticleParagraph">One patient also experienced a small improvement in an untreated eye. That unexplained effect in part highlights the limitations of acuity tests, which are subject to factors such as general health, mood and the placebo effect.</p>
<p class="articleParagraph enarticleParagraph">Indeed, experts said, there is no way short of an autopsy to know whether the injected genes integrated into the retinal cells and are functioning.</p>
<p class="articleParagraph enarticleParagraph">The British study, using a somewhat different viral vehicle made by <span class="companylink">Targeted Genetics</span> of Seattle, treated three patients, ages 17 to 23. Only one-third of the retina of each treated eye was injected, out of an abundance of caution. One patient had significant improvement in light sensitivity, but none had better acuity.</p>
<p class="articleParagraph enarticleParagraph">In both studies, some patients were for the first time able to get through a cluttered, dimly lit room unaided, according to the reports. They will be published in May but were released yesterday to coincide with a presentation at a medical conference.</p>
<p class="articleParagraph enarticleParagraph">"Before treatment, you can see he bumps into the walls and he's disoriented and has to be pointed in the right direction. He clearly just feels his way around," Ali said of one patient, who was videotaped before and after. "Six months after surgery, he could walk through without bumping into anything and take the same length of time that a normal person could."</p>
<p class="articleParagraph enarticleParagraph">That patient, Steven Howarth, said in a statement released by <span class="companylink">Targeted Genetics</span> that he is pleased.</p>
<p class="articleParagraph enarticleParagraph">"Now, my sight when it's getting dark or it's badly lit is definitely better. It's a small change -- but it makes a big difference to me," Howarth, 18, said.</p>
<p class="articleParagraph enarticleParagraph">Paul A. Sieving, director of the National Eye Institute, which led the research that identified the rpe65 gene but was not involved in the latest research, said Howarth's anecdote jibes with his observation that even modest improvements in vision can make for big gains in the quality of one's life.</p>
<p class="articleParagraph enarticleParagraph">"From the numbers, you can't imagine there's any real improvement," Sieving said. "But if I give you just a little vision, someone on the street can't even tell you have an impairment."</p>
<p class="articleParagraph enarticleParagraph">About 450 genes have been implicated in eye diseases, Sieving said, suggesting that the approach could have potential for many.</p>
<p class="articleParagraph enarticleParagraph">Arthur W. Nienhuis, president of the American Society of Gene Therapy and a faculty member at St. Jude Children's Research Hospital in Memphis, called the results "highly encouraging."</p>
<p class="articleParagraph enarticleParagraph">"I think the field is really beginning to turn the corner," Nienhuis said.</p>
<p>http://www.washingtonpost.com[http://www.washingtonpost.com]</p>
<p>WP20080428BLIND28</p>
<p>Document WP00000020080428e44s0001u</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>Gene therapy offers hope to blind</b>
</div><div class="author">Thomas H. Maugh II   </div><div>Los Angeles Times</div>
<div>32 words</div><div>28 April 2008</div><div>The News & Observer</div><div>RNOB</div><div>Final</div><div>A4</div><div>English</div><div>Copyright (c) 2008 by The News & Observer Pub. Co.   </div>
</p>
<p class="articleParagraph enarticleParagraph">The News & Observer does not own the rights to republish this article. See microfilm for full text.</p>
<p>Document RNOB000020080428e44s0000g</p></div><br/><span></span><div  class="article enArticle"><p>
<div id="hd" ><b class='enHeadline'>U.S. News: Gene Holds Hope for a Blindness Cure</b>
</div><div class="author">By Keith J. Winstein   </div><div>467 words</div><div>28 April 2008</div><div>The Wall Street Journal</div><div>J</div><div>A4</div><div>English</div><div>(Copyright (c) 2008, Dow Jones & Company, Inc.)   </div>
</p>
<p class="articleParagraph enarticleParagraph">A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.</p>
<p class="articleParagraph enarticleParagraph">About 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's retina, causing blindness and gradual deterioration of the eye's light sensors.</p>
<p class="articleParagraph enarticleParagraph">On Sunday, the New England Journal of Medicine published reports from two groups -- at the Children's Hospital of Philadelphia and at University College London -- who experimented on six blind patients by injecting good copies of the necessary gene, known as RPE65, into their eyes. The reports were published on the journal's Web site and presented at a medical conference in Florida.</p>
<p class="articleParagraph enarticleParagraph">Although preliminary, the results showed a modest improvement in vision, even though the patients studied were older than 18 and their eyes' sensors had largely deteriorated. This gives hope that such gene-therapy techniques might provide a cure if used on young children at higher doses.</p>
<p class="articleParagraph enarticleParagraph">In the U.S. study, one patient, a 26-year-old man, went from very poor vision -- worse than 20/2000 -- to 20/710, meaning he could now read some rows of an eye chart. The other two U.S. patients also improved. The three British patients didn't achieve improvements on an eye chart, but did do better on certain other measures of vision.</p>
<p class="articleParagraph enarticleParagraph">More importantly, none of the six patients experienced a serious side effect from the added gene, giving doctors the go-ahead to experiment with larger doses and on younger patients.</p>
<p class="articleParagraph enarticleParagraph">Gene-therapy techniques have led to much hope over the last 20 years, and about as much disappointment. Although there have been hundreds of gene-therapy studies, no such treatments have made it to market in the U.S. Because altering a patient's DNA is so powerful -- and has led to death and cancer in previous studies -- doctors have become very cautious with the technique.</p>
<p class="articleParagraph enarticleParagraph">Jean Bennett, the Philadelphia doctor who led the U.S. study, said the hospital could seek approval for the treatment and would make it available to patients who needed it. She wasn't optimistic that a pharmaceutical company would want to sell the treatment. "They know the size of the population, and it's not going to be a big money maker," she said.</p>
<p class="articleParagraph enarticleParagraph">License this article from Dow Jones Reprint Service[http://www.djreprints.com/link/DJRFactiva.html?FACTIVA=wjco20080428000023]</p>
<p>Document J000000020080428e44s0000g</p></div><br/><span></span><div  class="article enArticle"><p>
<div>News</div>
<div id="hd" ><b class='enHeadline'>'Our goal is to wipe it out': Cubs star joins fight to cure eye disease afflicting daughter  </b>
</div><div class="author">Toni Ginnetti  </div><div>The Chicago Sun-Times</div>
<div>829 words</div><div>30 September 2006</div><div>Chicago Sun-Times</div><div>CHI</div><div>Final</div><div>04</div><div>English</div><div> 2006 Chicago Sun Times.  Provided by ProQuest Information and Learning.  All rights reserved.
  </div>
</p>
<p class="articleParagraph enarticleParagraph">There were no tears Friday. Derrek Lee's desperate sadness over his daughter Jada's incurable genetic eye disease has inspired an upbeat determination in the Cubs first baseman to help find a cure.  </p>
<p class="articleParagraph enarticleParagraph">At a Wrigley Field news conference, Lee announced his mission: starting a foundation aimed at finding a cure for Leber's Congenital Amaurosis (LCA).  </p>
<p class="articleParagraph enarticleParagraph">LCA is an inherited form of blindness that usually is manifested soon after birth. Lee's 3-year-old daughter manifested the symptoms within the last month, but only in one eye.  </p>
<p class="articleParagraph enarticleParagraph">"She's still seeing very well out of one eye," Lee said. "We view that as a positive, and in that sense we continue to ask for prayers that she continues to have vision in that eye. We still believe that can happen."  </p>
<p class="articleParagraph enarticleParagraph">3,000 PEOPLE SAID TO BE AFFLICTED  </p>
<p class="articleParagraph enarticleParagraph">The same rare disease afflicts one of the children of Boston Celtics owner Wycliffe Grousbeck, whom Lee met after specialists told him of their shared situation.  </p>
<p class="articleParagraph enarticleParagraph">They have teamed to form a foundation called Project 3000 aimed at getting the estimated 3,000 people in the United States who are afflicted by LCA to undergo genetic testing to further research to find a cure.  </p>
<p class="articleParagraph enarticleParagraph">"It's something that's devastating initially when you're told something is wrong with your child," Lee said. "It's hard to explain unless you're a parent. You do anything for your child, and you're told there's nothing you can do, it's a tough pill to swallow.  </p>
<p class="articleParagraph enarticleParagraph">"As parents, we want to raise awareness and help other families out, and if there's a cure, we want to find it."  </p>
<p class="articleParagraph enarticleParagraph">LINKED TO A RECESSIVE GENE  </p>
<p class="articleParagraph enarticleParagraph">Lee's demeanor was much different than it was Sept. 17, when he choked back tears and announced he would miss the rest of the season to tend to Jada.  </p>
<p class="articleParagraph enarticleParagraph">The defending National League batting champion donned his Cubs uniform and took batting practice Friday for the first time since that announcement, and he even joked a bit with teammates. Lee may play today or in the season finale Sunday.  </p>
<p class="articleParagraph enarticleParagraph">In the past decade, research has linked the cause of the retina- damaging disease to a recessive gene that both parents must possess to pass on to a child. The hope is that identifying as many LCA- afflicted patients as possible will broaden the genetic profile of the disease and aid in finding a cure.  </p>
<p class="articleParagraph enarticleParagraph">The foundation will work with the John and Marcia Carver Nonprofit Genetic Testing Laboratory at the University of Iowa. That's where the Lee family was sent to meet Dr. Ed Stone, considered one of the foremost experts on LCA.  </p>
<p class="articleParagraph enarticleParagraph">"Dr. Stone is one of the best," Lee said. Stone put Lee in touch with Grousbeck, who has a child similarly afflicted. Grousbeck already is active in charitable causes in the Boston area, including Children's Hospital of Boston, Perkins School for the Blind and the National Braille Press, among others.  </p>
<p class="articleParagraph enarticleParagraph">The foundation has established a Web site for information at  www.carverlab.org/project3000 [http://www.carverlab.org/project3000].  </p>
<p class="articleParagraph enarticleParagraph">"We want everyone who was diagnosed with this in your life to go get tested," Lee said, adding the new foundation will provide financial aid for the effort. "It's very important. Ten years ago if you had this, they told you there was basically nothing you could do. You just go home. There was no genetic testing. They didn't know the gene responsible for this disease."  </p>
<p class="articleParagraph enarticleParagraph">ONLY 500 TESTED SO FAR, LEE SAYS  </p>
<p class="articleParagraph enarticleParagraph">"Now there's something you can do, so we want people to get tested. It's such a rare disease that if we can get all 3,000 people tested, patients down the road will have better information. So we think it's something important. Our goal is to wipe it out. We want to get rid of it and find a cure. That's what we're here to do."  </p>
<p class="articleParagraph enarticleParagraph">Lee said only 500 afflicted people have undergone genetic testing. "We need to get everyone with this disease tested to find the genes responsible and find a cure," he said. "There are clinical trials going on, and we're close to finding a cure." He said dogs and chickens with a similar condition have had vision restored through gene therapy.  </p>
<p class="articleParagraph enarticleParagraph">"Obviously, it's not humans, but it's progress," Lee said.  </p>
<p class="articleParagraph enarticleParagraph">Lee expressed thanks for the outpouring of support his family has received in the weeks since his daughter's condition developed. "It means a lot to us," he said.  </p>
<p class="articleParagraph enarticleParagraph">tginnetti@suntimes.com  </p>
<p>Photo: Cubs first baseman Derrek Lee is shown Sept. 17, when he
announced he would sit out the rest of the season because of his
daughter's illness. "If there's a cure, we want to find it," Lee
said Friday.  </p>
<p>Document CHI0000020060930e29u00006</p></div><br/><span></span><div id="lastArticle"  class="article enArticle"><p>
<div>ZONE</div>
<div id="hd" ><b class='enHeadline'>Parents set sights on vision breakthrough  </b>
</div><div class="author">Meredith Wade  </div><div>COMMUNITY NEWS WRITER</div>
<div>618 words</div><div>28 July 2006</div><div>The San Diego Union-Tribune</div><div>SDU</div><div>NC</div><div>NC-4</div><div>English</div><div> 2006 San Diego Union Tribune Publishing Company.  Provided by ProQuest Information and Learning.  All Rights Reserved.
  </div>
</p>
<p class="articleParagraph enarticleParagraph">CARMEL VALLEY -- Sometimes sight involves more than perceiving the world through a pair of eyes -- it involves a vision for the future.  </p>
<p class="articleParagraph enarticleParagraph">The Vision of Children Foundation is a Carmel Valley-based organization established in 1990 to eradicate hereditary childhood blindness and vision disorders and to improve the quality of life of visually impaired individuals and their families.  </p>
<p class="articleParagraph enarticleParagraph">Sam and Vivian Hardage created the foundation after one of their four children was diagnosed with ocular albinism.  </p>
<p class="articleParagraph enarticleParagraph">"When our son was diagnosed at 2 months old, we were stunned to find out that no one in the world was doing research in this area," Vivian said. "Doctors just told us there was no cure, no treatment, and to go home and be glad our son was not totally blind."  </p>
<p class="articleParagraph enarticleParagraph">Ocular albinism is a genetic disorder that affects the amount of pigment in the eyes, hair and skin. The disease can result in a loss of vision; uncontrollable, rapid movement of the eyes; crossed eyes; and sensitivity to bright light.  </p>
<p class="articleParagraph enarticleParagraph">The Hardages refused to accept that they could not help their son. When he was 2, they found a team of Italian scientists who were conducting research on the genetic causes of childhood blindness, specifically ocular albinism. The couple pledged to financially support the researchers in their attempts to identify the gene causing the disorder, clone the disease and develop an infected mouse model.  </p>
<p class="articleParagraph enarticleParagraph">"When we started doing this stuff 15 years ago, genetic research was a pretty far-out idea," Vivian said.  </p>
<p class="articleParagraph enarticleParagraph">"Neither one of us had any scientific knowledge in this area," Sam said. He worked in the hospitality industry, and Vivian was a former educator.  </p>
<p class="articleParagraph enarticleParagraph">"Our goal is simple," Sam said. "We want to find a cure and go out of business."  </p>
<p class="articleParagraph enarticleParagraph">So far, researchers have determined the disease is carried in females. A woman with the gene linked to ocular albinism has a 50 percent chance of passing the disease to her son.  </p>
<p class="articleParagraph enarticleParagraph">Although there are no current treatments for ocular albinism, a test has been developed using funding from The Vision of Children Foundation to determine whether a mother is a carrier of the disease.  </p>
<p class="articleParagraph enarticleParagraph">Health-care statistics in the United States do not record the frequency of the disease, but estimates are between 1 in 20,000 and 1 in 50,000 persons.  </p>
<p class="articleParagraph enarticleParagraph">Through the coordination of The Vision of Children Foundation, more than 500 families around the world have created a network of support and camaraderie.  </p>
<p class="articleParagraph enarticleParagraph">"We don't want these parents to feel like they are alone. We want them to know we are looking for a cure and that there is support out there," Vivian said.  </p>
<p class="articleParagraph enarticleParagraph">"The cavalry is on the way," Sam said. "There is a person on the Earth today who is blind and will one day be able to see because of this gene therapy."  </p>
<p class="articleParagraph enarticleParagraph">In addition to its other functions, the foundation has recently developed a computer monitor the Hardages hope to install in every learning center in the country. The monitor is attached to an adjustable arm so a visually impaired person can choose the height and angle of the screen to use a computer more easily.  </p>
<p class="articleParagraph enarticleParagraph">The Vision of Children Foundation depends solely on supporter contributions to maintain its research, outreach and education programs. For more information on the organization, call (858) 799- 0810 or visit  www.visionofchildren.org [http://www.visionofchildren.org].  </p>
<p>1 PIC;
Caption: Sam Hardage founded The Vision of Children Foundation after
his son was born with a vision impairment. The Carmel Valley-based
organization helps fund research and serves as a support network for
families.;
Credit: Nadia Borowski Scott / Union-Tribune  </p>
<p>Document SDU0000020060730e27s00022</p></div><br/></div></div><span><div id="pageFooter"><table width="100%" cellspacing="0" cellpadding="0" border="0" class="footerBG">
	<tr>
		<td nowrap="nowrap" width="100%" align="right"><span class="copyright">&copy; 2011 Factiva, Inc.  All rights reserved.</span></td>
		<td><div class="ftright">&nbsp;</div></td>
	</tr>
</table>
<span class='shadowL'></span><span class='shadowR'></span></div></span></form><script type='text/javascript'>framesViewNotReqd = false;modalEnabled = true;modalPopupIframeDefaultSource='/blank.htm';RequestFromModal=false;RequestFromIPad=false;</script>
</body>
</html>